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ABSTRACT
The MIR137HG gene encoding microRNA-137 (miR-137) is associated with risk for
schizophrenia (SZ) through genetic and functional studies, however, the molecular mech-
anisms underlying risk remain unknown. Through this work we characterize MIR137HG
genetic risk architecture and describe novel regulatory mechanisms that contribute to neu-
rodevelopment and potential etiology for SZ. Case-control haplotype analyses revealed novel
MIR137HG common and rare haplotype associations. Multiple genetic variants contribute
to these diagnostic associations including a nearby variable number tandem repeat (VNTR)
element. Through transcript characterization at early and late developmental time points
we found novel del-miR-137 splice variants that down regulate mature miR-137 expression
through alternative 5′ splicing within the pre-miR-137 sequence in exon 3. Importantly,
we found significant positive associations between del-miR-137 transcripts and early devel-
opment as well as VNTR length. We present a novel regulatory mechanism for miR-137
through increased regional GC% content and localization of the microRNA biogenesis reg-
ulator methyl-CpG-binding protein 2 (MECP2). Additionally, we describe putative novel
competitive endogenous RNA (ceRNA) function for del-miR-137 transcripts. Through se-
quence structure analysis we describe a potential isomiR of miR-137 overlapping the canoni-
cal sequence. Lastly, we detail genetic variants in the context of human evolution and overall
associations with complex disease.
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The microRNA-137 (miR-137) is a critical regulator of neurodevelopment and mainte-
nance that has been associated with a number of neurological disorders including schizophre-
nia (SZ). SZ is a severe neuropsychiatric disorder that is highly complex, and despite decades
of research the underlying etiology is still unknown. The first large genome wide association
studies (GWAS) of SZ implicated the MIR137HG locus. Since that time, numerous studies
have supported the role of miR-137 in the pathobiology of SZ. This body of work will review
current scientific understanding of miR-137 function and investigate novel molecular mecha-
nisms contributing to brain development and disease, with a specific focus on the etiological
role in SZ.
I.1 Human Brain Development
No other organ exemplifies cellular diversity like the human brain, which is the most
complex tissue in the human body with unrivaled information processing ability. This com-
plexity is evident on multiple scales both temporally and spatially. It has been suggested
that the mammalian central nervous system (CNS) contains 500–1000 different gray matter
regions, 2500–5000 neuron classes, and 25,000–100,000 macroconnections between neuron
classes.1 In adulthood the brain has approximately 170 billion neuronal and nonneuronal
cells forming numerous circuits through 100 trillion synaptic connections.2 These synaptic
connections can change on the scale of seconds to hours.3 Additionally, the brain changes
both structurally and functionally across development.4 Together all of these elements form
the physical and biological basis of cognition, including perception, attention, emotion and
action.
Human brain development is an extensive process that spans from the third gestational
week beginning with the differentiation of the neural progenitor cells until late adolescence
and potentially throughout the lifespan.5,6 Embryonic and early fetal periods of brain de-
velopment center around neural progenitor cell differentiation, neural tube formation and
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neural patterning.6,7 During the later fetal period, brain development centers around the
processes of neuron proliferation, migration, and differentiation.6 Neuron production begins
on embryonic day 42, and is largely complete by midgestation. Throughout the remainder of
gestation there is rapid growth and development of both cortical and subcortical structures,
including the migration of neurons to different brain regions where they begin to differen-
tiate and make connections forming rudimentary neural networks. In the early postnatal
period, the level of connectivity throughout the developing brain far exceeds that of adults.8
This connectivity is pruned throughout the postnatal period leading to structural changes
which continue through childhood and adolescence in both the major gray and white matter
regions.
I.1.1 Essential Role of MicroRNAs and MicroRNA-137 in Brain Development
and Neurological Diseases
The morphological and functional complexity and cellular specialization in the brain
depend on a highly coordinated gene expression program as well as environmental input,
both of which are essential for normal brain development, and disruption of either can fun-
damentally alter neural outcomes.6 Part of the brain’s regulatory gene expression program
includes small non-coding RNAs such as microRNAs (miRs) that are critical for neurodevel-
opment. MicroRNAs are a large class of endogenously expressed, single stranded RNAs ∼22
nucleotides (nts) in length, which post-transcriptionally repress messenger RNA (mRNA).
Analysis of the distribution of miRs across early branching animal phyla reveals an an-
cient origin for miRs in the Eumetazoan era ≈635 million years ago, around the same time
as the evolutionary origin of the gut and nervous system.9–11 Several miRNA expansions
are observed at the base of the bilaterian, nephrozoan, vertebrate, and placental mammal
lineages.9 These expansions demonstrate a correlation between the number of miRs and
increasing morphological complexity, suggesting that innovation at the post-transcriptional
gene regulatory level through miRNA expansion may have contributed to the evolutionary
emergence of complex organisms.10 It has been estimated that over 60% of protein-coding
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genes in the human genome are regulated by miRs and about 50% of all identified miRs
are expressed in the mammalian brain.12,13 Several studies have shown that many criti-
cal processes in the brain such as cell proliferation, differentiation, migration, and death
require precise regulation by miRs throughout development.12,14–16 MicroRNAs have also
been shown to modulate dendritic and synaptic morphology and function.17 A single miR
can modulate extensive biological networks with thousands of target genes.
One particular miR, miR-137 is associated with several of these processes including the
regulation of neuronal maturation, dendritic development, adult neurogenesis, as well as
dynamic control of neural stem cell proliferation and differentiation. miR-137 was first iden-
tified in 2002 in mouse cortical tissue and was shown to be conserved and expressed in both
mammalian and nonmammalian vertebrates.18 The Nephrozoan expansion of miRs ≈550
mya coincided with the emergence of the central nervous system including neurosecretory
cells in a primitive brain.10,19 These early neurosecretory cells were characterized by expres-
sion of miR-137,9,10 establishing miR-137 as a fundamental neurodevelopmental regulator.
With the critical role that miR-137 plays in the brain, it is not surprising that dysregulation
of this miR has been associated with several neurological and neuropsychiatric disorders.
Interestingly, studies involving microdeletion of the MIR137HG 1p21.3 region were the first
to demonstrate that disruption of a single miR can lead neurological and cognitive disfunc-
tion.20,21 Since that time, miR-137 has been linked to multiple brain disorders including
SZ, major depression, bipolar disorder (BD), autism spectrum disorder (ASD), Hunting-
ton’s disease (HD), Rett syndrome, and intellectual disability. Many of these disorders have
overlapping phenotypes as well as shared biological risk factors.22 Understanding canoni-
cal function of regulatory pathways such as that of miR-137 is critical for making progress
towards better diagnostics and treatments for these devastating disorders.
I.2 Schizophrenia Background
The MIR137HG locus was initially associated with SZ through GWAS.23 Much of the
enthusiasm surrounding miR-137 research is due to the possibility that it may play a role in
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SZ pathobiology. However, despite extensive research, many questions remain unanswered
about the link between miR-137 and SZ. SZ is a severe neuropsychiatric disorder affecting
approximately 1% of the population worldwide. Although the prevalence is low, the health,
social, and economic burden of disease has been immense. In the US, the economic burden
of SZ is found to be more than $60 billion per year.24 Several factors including the early
age of onset (typically between 18 and 35 years of age) and the chronic nature of disease
contribute to the substantial disease burden, and make SZ a particularly disabling disorder
for patients and their families.
Since the age of antiquity, symptoms relating to SZ have been described. The Swiss psy-
chopathologist Eugen Bleuler first coined the term schizophrenia in 1911 from the greek roots
schizein meaning ’to split’ and phren meaning ’mind’.25 SZ has been difficult to approach
from a clinical perspective, with a broad spectrum of associated psychiatric phenotypes, and
with limited knowledge of the underlying pathology, development of diagnostic tools and
treatments has been hindered. SZ is diagnosed today much the same way as it was in Eugen
Bleuler’s time.7 Current diagnosis is based on clinical phenotypes including positive, nega-
tive, and cognitive symptoms.26 Positive symptoms, otherwise known as psychotic symptoms
include hallucinations (hearing, seeing, tasting, smelling, or feeling sensations that are not
present) and delusions (fixed false beliefs or suspicions that are firmly held that do not align
with reality). Negative symptoms include impaired motivation, reduction in spontaneous
speech and social withdrawal. Cognitive symptoms include deficits in executive function.
Positive symptoms tend to remit and relapse, while the negative and cognitive symptoms
tend to be chronic and are associated with long-term effects on social function.27 There is
typically a prodromal phase which can include attenuated positive symptoms, mood symp-
toms, cognitive symptoms, social withdrawal or obsessive behaviors.28 There are currently
no objective medical tests or measurements to support a clinical diagnosis.7 Many of the
current treatments only target the intermittent psychotic symptoms and are ineffective for
the treatment of the more chronic negative and cognitive symptoms. Despite slow progress
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in diagnosis and treatment and incomplete knowledge of the pathoetiology of SZ, biological
research into the underlying causal mechanisms of SZ has progressed our understanding of
the disease substantially.
I.2.1 Neurotransmitters and Neuropathology
Many early studies of SZ pathophysiology centered around disruptions of neurotransmit-
ters, specifically the excitatory glutamatergic, the inhibitory GABAergic, and the dopamin-
ergic systems. Research in this area began after the discovery that antipsychotic drugs are
dopamine receptor antagonists. Additional studies focused on the glutamate receptor antag-
onists due to the psychomimetic effects of ketamine and phencyclidine. Excess dopaminergic
signaling is thought to contribute to SZ’s positive symptoms. Recent evidence suggests that
dopaminergic deficits may play a role in negative and cognitive symptoms as well. Glutamate
receptor NMDA hypofunction has been implicated in SZ, due to glutamatergic abnormalities
in post-mortem brains from patients with SZ. Decreased GABAergic function was implicated
in SZ pathology due to decreased expression of the GABA synthesizing enzyme, GAD, in
post-mortem brain tissue. Genetic research supports findings with numerous significant
variants found in loci containing genes involved in these neurotransmitter networks.
Early research has also established many associations between disease and structural
brain abnormalities. Global scale analyses have demonstrated a small but significant re-
duction in total brain volume and a significant enlargement of the ventricles in patients
with SZ.26 Postmortem and imaging studies have found deficits in both white matter and
gray matter in the prefrontal cortex.26 Lower synaptic and dendritic density was found in
the dorsolateral prefrontal cortex (DLPFC) in patients. Volume reductions in the temporal
lobe, including the amygdala-hippocampal complex have been found in both chronic and
first-episode patients. Hippocampal pyramidal neural shape has been reported to be altered
in first-episode patients with reduced cell body areas and longer and thinner morphology
compared to controls. Patients also exhibit decreased dendritic spine density and less apical
arborization in the hippocampus. Glutamate and GABA receptors and neurons also appear
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to be altered in this region in patients. The size and connectivity of the thalamus is also
decreased in patients. These various subtle changes in brain structure reflect the challenge
of studying a complex disorder such as SZ in which there is great variation in the clinical
presentation likely involving distinct but interrelated neuropathological deficits.
I.2.2 The Neurodevelopmental Model
SZ is widely considered to be a neurodevelopmental disorder with pathogenic factors
occurring early on in life that disrupt the normal course of neural development and increase
vulnerability long before the formal onset of illness.29–33 Multiple lines of evidence support
the neurodevelopmental model for SZ. Initially, results of epidemiological research suggested
a developmental disease origin. Studies found multiple prenatal and perinatal risk factors
including: maternal infection, maternal malnutrition, and obstetric complications. Recently,
genetic findings have highlighted the polygenic architecture of SZ and contributed to the
neurodevelopmental model.
I.2.3 Genetic Research
Heritability estimates for SZ are high ranging from 50-80%, and concordance rates be-
tween identical twins is approximately 50%. It is tempting to assume that a large heritability
would facilitate discovery of underlying genetic associations, however initial attempts to find
SZ associated variants through GWAS were hampered by the lower than expected effect sizes
of risk genes. With odds ratios (ORs) typically below 1.2, early GWAS from 2006-2009 were
underpowered to detect genome-wide associations.34 Increased sample sizes led to the first
genome-wide associations found from 2009 - 2011, implicating the major histocompatibility
complex (MHC) region, neurogranin (NRGN), and transcription factor 4 (TCF4).35–37 A
large GWAS for SZ conducted by the Psychiatric GWAS Consortium (PGC) (36,989 cases
and 113,075 controls) found 108 genetic loci to be significantly associated with diagnosis.38
The largest and most recent GWAS found an additional 50 novel SZ loci and 145 loci in
total.39 Associated risk variants are common alleles with small effect sizes (ORs<1.3). These
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findings support the highly polygenic nature of SZ, suggesting that many genetic variants
with small effect sizes combine to contribute to increased SZ risk. Genomic studies have also
identified a number of rare recurrent copy number variants (CNVs), which are large regions
of the genome that have been deleted or duplicated.40 These rare CNVs typically have larger
effect sizes OR of 4-70.
Interestingly, the genetic risk architecture is highly pleiotropic (i.e., one variant can affect
multiple phenotypic traits).7 This pleiotropy is seen for both common and rare variants with
shared common risk between a number of psychiatric disorders. Common risk variants are
found to be shared between SZ, BD, major depressive disorder, attention deficit hyperactivity
disorder (ADHD), and ASD.22 Rare SZ risk variants have been found to be associated with
generalized epilepsy and a number of childhood neurodevelopmental disorders including ASD,
intellectual disability, developmental delay, and ADHD.41–44 Exome-sequencing studies have
also found rare single nucleotide variants (SNVs) and insertions and deletions (indels) that
are associated with a similar range of phenotypes.45 This genetic pleiotropy supports the
idea that SZ and other psychiatric disorders are on a continuum.7,46
Despite this high rate of heritability, and large pool of genetic associations, the underlying
genetic mechanisms of SZ are poorly understood. The majority of the associated single
nucleotide polymorphisms (SNPs) are located in noncoding regions of the genome, suggesting
risk regions may play a role in regulating gene expression.47 Convergent evidence from
functional analyses of genetic risk variants indicate several biological processes that may
contribute to SZ etiology. Biological pathways found through in silico analysis include a
number of synaptic proteins, including components of the post-syntaptic density (PSD)
protein and voltage-dependent calcium channel family proteins.48 Transcriptome analyses
have showed that the prenatal period is enriched for SZ risk loci providing further support for
the developmental hypothesis.49,50 Network analysis in these studies have implicated synaptic
processes, including shared pathways between SZ, ASD, and BD involving postsynaptic
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density, dendritic compartments, receptor-mediated presynaptic signaling and inflammatory
signaling.50,51
I.2.4 Environmental and Epigenetic Associations
Many epigenetic regulatory factors have been associated with SZ including DNA methy-
lation. Interestingly, many environmental risk factors for SZ are linked to DNA methylation
changes in both humans and mice including maternal stress and infections, obstetric com-
plications, and maternal nutrition during pregnancy.52–58 Jaffe et al. mapped global DNA
methylation in the human prefrontal cortex and showed that differentially methylated re-
gions (DMRs) between fetal and postnatal samples are enriched for SZ GWAS risk loci.59
The majority of these DMRs follow a pattern of increased fetal DNA methylation compared
to postnatal methylation. Evaluation of DMRs in SZ patients versus controls in both brain
and blood demonstrates a consistent pattern of hypomethylation in patients.59–61 These
results are accordant with the neurodevelopmental hypothesis model; if a person has risk
factors that predispose them to hypomethylation in regions of the brain which are typically
hypermethylated early in development that could lead to long-term neurodevelopmental
consequences, which may only become apparent after additional environmental insult.
I.2.5 Childhood Onset Schizophrenia
Childhood onset schizophrenia (COS) is a rare form of SZ with an estimated prevalence
of 1/10,000 and is defined by the onset of psychotic symptoms before the age of 13.62 Earlier
age of onset has been associated with progressive structural variations in the brain including:
reduced hippocampal volume, increased lateral ventricle volume, and decreased white matter
integrity.63,64 Longitudinal studies show that these brain changes are more robust than in
AOS.65 In addition, compared with adult onset patients, earlier onset patients have a higher
incidence of prepsychotic developmental disorders.66 COS is thought to be a more genetically
severe form of the disorder, associated with a higher rate of copy number variants in genes
associated with pathways of neuronal development and regulation, compared to adult onset
schizophrenia (AOS) patients.62 However, due to the rare nature of COS, the large sample
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sizes needed for genome wide significant associations are not attainable. Other strategies,
such as candidate gene approaches must be used to evaluate the etiology of COS.
I.3 Support for the Role of MicroRNA-137 in the Etiology of Schizophrenia
I.3.1 Genome Wide Associations
In 2011 the first large-scale SZ GWAS was conducted by the PGC and included more
than 20,000 samples; five novel loci were implicated.23 The MIR137HG gene is located on
chromosome 1p21.3 (hg38 chr1:97,988,000-98,049,863) and was implicated through its prox-
imity to the SNP rs1625579 (p=1.6e-11) located in MIR137HG intron 3. This association
was also supported in a cohort of Han Chinese individuals.67 Four predicted and subse-
quently validated target genes were also independently associated with SZ including TCF4,
CACNA1C, CSMD1, C10orf26.23,68 The miR-137 validated target gene ZNF804A also nearly
met genome-wide significance in subsequent studies.69,70 These genetic results indicated that
convergent pathways regulated by miR-137 may be contributing to SZ risk. Since that time,
numerous clinical phenotypic associations have been found with rs1625579. These findings
are summarized in Tables I.1 and I.2. A second GWAS found significant association with
the SNP rs1198588 (p=1.72e-12) located approximately 40 kb upstream of the MIR137HG
gene.70 In a larger GWAS again by the PGC (36,989 cases and 113,075 controls) 108 ge-
netic loci were found to be significantly associated with diagnosis; the MIR137HG locus
was the second most significant association (rs1702294, p=3.36e-19). GWASs conducted in
a Swedish population (p=2.58e-6) and an Ashkenazi Jewish population (p=1.02e-17) found
the MIR137HG SNP rs2660304 associated with diagnosis.71 The rs2660304 SNP was also a
top association in the most recent GWAS(p=2.18e-18).39,72 The major allele (T) is the risk
allele for all of the GWAS associations. Figure I.1 depicts the regional pattern of association.
I.3.2 MicroRNA-137 Expression
miR-137 is primarily and highly expressed in the brain particularly in areas of active
neurogenesis. In zebrafish, miR-137 is mainly expressed in both the CNS and peripheral
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Table I.1: GWAS SNP Genotype Associations
Variant Allele MAF Study type Associated with: Sample/Population References
rs1625579 T Major 0.21 GWAS Association with SZ Ripke et al.,2011
Clinical symptoms Earlier disease onset SZ patients Lett et al.,2013
Less severe positive symptoms,
working memory and attention deficits
SZ patients Cummings et al.,2013
Decreased working memory performance
TT vs G allele carriers in Han Chinese
SZ patients (Han Chinese) Ma et al.,2014
More severe negative symptoms,
worse attention and processing speed
SZ patients Kuswanto et al.,2015
Greater symptom severity SZ patients Kandratsenka et al.,2018
Reduced auditory P300 amplitude (did not
reach bonferroni-corrected significance)
SZ patients Decoster et al.,2012
miR-137 expression Decreased expression in DLPFC Control subjects Guella et al.,2013
Brain structure
Decreased fronto-striatal brain white
matter integrity
SZ patients Kuswanto et al.,2015
Decreases in occipital, parietal and
temporal lobe gray matter concentration
SZ patients Wright et al.,2016
Reduced white matter integrity, smaller
hippocampus, larger lateral ventricles
SZ patients Lett et al.,2013
Reduced white matter integrity and
cortical surface area, TT vs G carriers
1st degree relatives of patients Vogel et al.,2018
Brain function
Higher left DLPFC activation TT vs
G carriers
SZ patients and controls van Erp et al.,2014
Higher connectivity between DLPFC
& left hippocampi vs heterozygotes
Control subjects Liu et al.,2014
Increased connectivity between right
amygdala & frontal regions
Control subjects Mothersill et al.,2014
Decreased activation in left amygdala & left
pre/postcentral gyrus for TT vs G carriers
1st/2nd degree relatives of patients Whalley et al.,2012
SZ-schizophrenia; DLPFC- dorsolateral prefrontal cortex; MAF- minor allele frequency;
Table adapted from Sakammoto and Crowley, 2017 and Thomas et al.,2018; Table continued on next page10
Table I.2: GWAS SNP Genotype Associations Continued
Variant Allele MAF Study type Associated with: Sample/Population References
rs1625579 G Minor 0.21 Clinical symptoms
Carriers with severe negative symptoms
more likely to have cognitive deficits
SZ patients Green et al.,2013
miR-137 expression Increased miR-137 levels Patient fibroblast-derived neurons Siegert et al.,2015
Brain structure
Reduced cortical surface area for
carriers relative to TT control subjects
Control subjects Vogel et al.,2018
Greater reduction in volume of mid-posterior
corpus callosum relative to TT patients
SZ patients Patel et al.,2015
Brain function
Higher activation in the left amygdala & left
pre/postcentral gyrus for carriers vs TT
Control subjects Whalley et al.,2012
Higher activation in the right posterior
medial frontal gyrus
Control and 1st/2nd degree
relatives of SZ or BD patients
Whalley et al.,2012
rs1198588 T Major 0.22 GWAS Association with SZ, p=1.72e-12 Ripke et al.,2013
Clinical symptoms Worse negative symptoms SZ patients Kuswanto et al.,2015
Brain function Reduced fronto-striatal connectivity SZ patients Kuswanto et al.,2015
A Minor miR-137 expression Increased miR-137 levels Patient fibroblast-derived neurons Siegert et al.,2015
Increased miR levels, increased chromatin
accessibility, reduced dendritic branching
hiPSC neurons from SZ patient Forrest et al.,2017
rs1702294 C Major 0.21 GWAS Association with SZ PGC, 2014
Clinical symptoms
Worse social cognition and
attentional control
Cosgrove et al.,2017
rs2660304 T Major 0.21 GWAS Association with SZ Duan et al.,2014
Association with SZ Ashkenazi Jewish Subjects Goes et al.,2015
miR-137 expression Decreased promoter activity Warburton et al.,2016
Lower miR-137 expression Control fibroblast-derived neurons Siegert et al.,2015
G Minor miR-137 expression Increased miR-137 levels Patient fibroblast-derived neurons Siegert et al.,2015
SZ-schizophrenia; DLPFC- dorsolateral prefrontal cortex; MAF- minor allele frequency;
Table adapted from Sakammoto and Crowley, 2017 and Thomas et al.,2018; Table continued from previous page
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Figure I.1: Plot from LocusZoom depicts the regional pattern of association. Chromosomal location is shown along the x
axis with gene locations depicted below. Each dot represents a SNP, with height relative to the log P-value along left y axis
indicating greater association with schizophrenia diagnosis. Color of each dot indicates linkage disequilibrium (LD) relative to
the rs1702294 SNP according to the LD color key. The blue line with peaks along the bottom of the plot indicates recombination
rate according to the right y axis. Moderately high LD in this region encompasses the entire MIR137HG gene. Many regulatory
elements are located within this block of LD which GWAS risk variants may be tagging that would contribute to SZ etiology.
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nervous systems at 3 days post fertilization, including strong expression in neurons and
cranial nerves and ganglia in fore-,mid- and hindbrain as well as sensory neurons and the
spinal cord.73,74
Microarray analysis of commercial human tissues showed miR-137 was expressed at a
low level across all tissues, but was most highly expressed in the brain.75 Northern blot
analysis showed that miR-137 was brain-enriched in both human and mouse tissues.13
The Genotype-Tissue Expression (GTEx) Consortium conducted RNA-sequencing data
from 54 distinct tissues in 237 postmortem donors. GTEx results for miR-137 show a low
level expression across nearly all tissues, but high expression in the brain particularly in the
frontal cortex.76 Many other studies support the finding of specific brain enrichment for
miR-137.77
Significant enrichment of miR-137 was found in mouse synaptosomes compared to cy-
tosolic fractions.78 Using commercially available RNA from human brain miR-137 was found
to be highly expressed in the hippocampus and occipital, frontal, and parietal cortical re-
gions, while low levels were detected in the brain stem and cerebellum.78
I.3.3 MicroRNA-137 Target Genes and the Genomics of Schizophrenia
Studies have determined that miR-137 acts as a gene network hub during synaptic de-
velopment, functioning upstream in many critical neurodevelopmental pathways that are
independently associated with SZ such as Nrg/ErbB, PI3K-Akt-mTOR, and MAPK/ERK
signaling.79–81 There is significant overlap between miR-137 target genes and genes asso-
ciated with SZ. Computational methods have found predicted miR-137 target genes are
enriched for smaller SZ GWAS p-values, indicating that miR-137 is a network node in SZ
risk gene pathways.23 Analysis of miR-137 target genes found that 74% of target genes have
peak expressions prenatally supporting a neurodevelopmental risk model for MIR137HG .82
Ultra-rare variants that were gene disruptive were found to be increased in patients, and
were significantly enriched with predicted miR-137 target genes.83 A GWAS conducted for
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genes involved in the SZ phenotype of DLPFC activation in brain imaging found enrichment
for predicted miR-137 target genes.84
I.3.4 Expression Associations with Risk Genotype
Multiple studies suggest that the SZ GWAS risk alleles are typically associated with
decreased miR-137 levels in control derived tissues (Tables I.1 and I.2). A post-mortem brain
study of DLPFC found that healthy individuals homozygous for the rs1625579 risk associated
T allele had decreased levels of miR-137 compared to G allele carriers80(See Appendix).
However, patients do not show this same pattern of expression. Patients in both the major
and minor genotype groups had elevated miR-137 expression levels similar to control G
allele carriers. In addition, the minor alleles of SZ associated SNPs (rs1198588, rs1625579,
rs2660304, and rs2802535) were associated with a significant increase of endogenous MIR137
levels in human fibroblast-derived neurons from patients compared to control derived tissues
with the major allele genotype.85 These results suggest that there may be aberrant increased
expression of miR-137 in patients.
A rare SNV 1:g.98515539A>T located in the enhancer region for MIR137HG was asso-
ciated with SZ and BD.86 In vitro analysis determined that the risk allele reduced enhancer
activity by over 50% and conversion of the risk allele to the major allele in neurons derived
from human induced pluripotent stem cells (hiPSC) increased promoter accessibility, tran-
scription and mature miR-137 levels.87 This same study found similar results for the GWAS
risk allele rs1198588 with correction to the major allele leading to increased promotor ac-
tivity, transcription and miR-137 levels.87 These results, although seemingly contradictory,
may represent an epistatic risk mechanism with these variants, as we demonstrate in Chapter
III the genetic region is complex and alleles confer differential risk based on the surrounding
haplotype block.
I.3.5 Clinical Associations with Risk Genotypes
The risk allele at SNP rs1625579 (T) is associated with a number of SZ phenotypes. Re-
duced amplitude of the auditory event-related potential P300 has been consistently reported
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in patients with SZ and there is evidence for possible association with risk variant rs1625579,
although it did not reach Bonferroni-corrected statistical significance.88–90 In SZ patients,
carriers of the risk allele had lower positive symptom factor scores and lower scores on a life-
time measure of psychosis incongruity. No association was found with negative symptoms,
however there was a significant association with cognitive deficits specifically with episodic
memory and attentional control.91 This indicates that risk allele carriers may represent a sub-
group of patients with lower psychotic symptoms but increased cognitive deficits.91 Patients
who were homozygous for the risk allele were found to have an earlier age-at-onset of psy-
chosis across four independently collected samples of patients with SZ.63 miR-137 polygenic
risk scores were generated from a miR-137 overexpression model in human neural progenitor
cell lines, and increased scores in both patients and controls were associated with signifi-
cantly lower performance on intelligence quotient, working memory and episodic memory,
consistent with previous findingsSZ.91–93 Brain imaging showed that increased polygenic risk
score was also associated with increased activation of the right inferior occipital gyrus, which
is speculated to be correlated with a relative inefficiency in processing in individuals with
higher risk scores.93 Overall these results demonstrate a consistent pattern of association
between miR-137 risk variants and cognitive deficits as well as earlier age of onset.
I.3.6 Macroscopic Brain Associations with Risk Genotype
Several studies have investigated the risk variant rs1625579 with brain structure varia-
tion. A significant association was found between risk genotype and white matter integrity
in the right orbitofrontal region of SZ patients.94 The effects of the rs1625579 genotype, a
genetic risk score based on variants in four miR-137 regulated genes, and diagnosis on gray
matter concentration was evaluated.95 Results of this multivariate analysis showed that
patients who were homozygous for the risk allele had significantly reduced grey matter con-
centration in the occipital, parietal and temporal lobes with increasing miR-137 genetic risk
score; these changes were not seen in control subjects.95 Patients who had the risk genotype
had reduced white matter integrity throughout the brain in addition to smaller hippocampi
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and larger lateral ventricles;63 subjects who were carriers of the non-risk alleles had no sig-
nificant differences in brain structure from healthy control individuals. Two other studies
including patients and controls96,97 and several other studies with only healthy controls ex-
amined brain structure associations with the rs1625579 risk MIR137HG variant and found
no significant associations.95,98,99 Patel et al.97 found that patients with the risk genotype
had significantly smaller mean corpus callosum volume than the volume of all controls. This
result supports previous findings in SZ.
Functional imaging studies of the brain have also found associations with risk SNP
rs1625579. In healthy controls, the risk genotype was found to be associated with higher left
DLPFC activation100 as well as significantly higher functional connectivity between DLPFC
and left hippocampi than non-risk allele carriers.101 Increased functional connectivity was
found between the right amygdala and frontal regions in healthy subjects who were homozy-
gous for the risk allele.102 An effect of genotype was found in the right posterior medial
frontal gyrus with a reduced gradient of brain response in individuals with the risk genotype
in both patients and controls relative to non-risk allele carriers.103 This same group found
overactivation in the amygdala in patients with the risk genotype.103 A pattern of increased
activation in the risk genotype group was seen in the pre/postcentral gyrus in patients, the
opposite pattern was seen in controls.103
I.4 Essential MicroRNA Background: Biogenesis, Processing and Mechanism
of Action
In order to understand how miR-137 may contribute to the etiology of SZ we first need
to understand canonical miR biogenesis and function. A single miR can regulate expression
of thousands of target genes, and indeed miR-137 has over 1,300 predicted target mRNA
transcripts according to the latest estimate in TargetScan v.7.2.104 Thus, even subtle changes
in miR function may have far reaching biological consequences and play an important role
in pathoetiology. For this reason, it is critical to understand typical regulation of miRs such
as miR-137.
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A schematic of miR biogenesis is depicted in Figure I.2 from Spence et al., 2016.105
Briefly, a miR is processed through several steps. Initially, the miR gene is transcribed into
a primary microRNA (pri-miR), which is typically several kilobases (kb) long. The pri-miR
is then recognized and cleaved into a ∼70 nt stem-loop structure known as the precursor
microRNA (pre-miR). The pre-miR is exported out of the nucleus and cleaved a second
time into a short double-stranded RNA (dsRNA). One of these strands will become the final
mature miRNA that will bind to and down-regulate expression of target gene mRNA.
I.4.1 Transcription and Nuclear Processing
Biogenesis of miRs begins with transcription of the miR genomic sequence. Transcrip-
tion is carried out by RNA polymerase II (Pol II) and typically results in a single-stranded
pri-miR, which is ∼62kb long and contains both a 5′ cap and a poly(A) tail.106 Once the
pri-miR is transcribed, it then forms a ∼70nt secondary stem-loop structure. The pri-miR
hair-pin is then recognized and cleaved by the Microprocessor complex, a large protein
complex comprised of one nuclear RNAse III enzyme DROSHA and two molecules of its co-
factor the dsRNA-binding protein DGCR8 along with other proteins. There is evidence that
both co-transcriptional and post-transcriptional processing of nascent pri-miR transcripts
occurs.107,108 Transcriptional termination is known to be coupled with the 3′-end processing
of RNAs, however, microprocessing of pri-miRs located within long non-coding RNAs (lncR-
NAs) has also been shown to mediate transcript termination.109,110 Several cis-acting
pri-miR sequence elements affect the efficiency of processing in their basal, stem, and apical
parts and are shown in FigureI.3(a).111 MicroRNAs bind to target gene mRNA through
their “seed” sequence which is at the 2-8 nt position relative to the 5′ end of the miRNA.
Alteration of the seed sequence by even a single base can drastically alter targeting speci-
ficity. Therefore, processing of miRNAs requires perfect fidelity. The basal part of pri-miRs
contains a UG sequence around the basal junction (positions -14 to -13 on the 5p strand)
termed the “basal UG”, and a CNNC sequence (N, any nt) in the flanking 3′ sequence termed
the “flanking CNNC”. The lower stem contains a mismatched GHG (mGHG) motif. The
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Canonical miRNA Processing
Figure I.2: Biogenesis of microRNAs occurs through several steps. Transcription of the
primary RNA (pri-miR) is carried out by RNA pol II. The RNA secondary structure forms a
stem loop that is recognized and cleaved by the microprocessing complex containing DGCR8
and the nuclear RNAse III enzyme DROSHA. Once the precursor miRNA (pre-miR) is
cleaved it is then exported out of the nucleus and cleaved by the cytoplasmic RNAase III
enzyme Dicer. One strand is then loaded into the RNA-induced silencing complex (RISC)
along with the target gene mRNA and depending on binding affinity of the seed sequence
the RISC will cleave the mRNA or initiate transcriptional repression. Adapted from from
Spence et al., 2016.
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Figure I.3: (a) Pri-microRNA (pri-miRNA) sequence elements that effect microprocessor
cleavage efficiency are depicted on the left. Microprocessor complex binding relative to pri-
miRNA structure is depicted on the right. H nucleotides represent A, C or U; N nuleotides
represent all nucleotides. SRSF3 - serine/arginine-rich splicing factor 3. Figure adapted from
Treiber et al., 2019. (b) Pri-miR-137 structure with important microprocessing sequence
elements highlighted in blue. Drosha cleavage sites are indicated by red arrows.
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apical part of pri-miRs contains UGU or GUG sequences around the apical junction on the
5p strand termed the “apical UGU”. All of these motifs increase the processing efficiency of
DROSHA. The UG and UGU motifs ensure the correct orientation of pri-miRs when binding
to the Microprocessor complex. The mGHG motif plays a critical role in determining the
DROSHA cleavage site. DROSHA will cleave precisely 7 bp away from the mGHG site.112
This same study also showed that the basal junction is used as a reference point over the
apical junction in absence of the other sequence motifs, and is therefore more important than
the apical junction in cleavage site determination. These critical sequence GHG, UG, and
CNNC elements for the primary microRNA-137 (pri-miR-137) structure are highlighted in
I.3(a). The pri-miR-137 lacks an apical UGU motif on the 5′ strand.
The resulting “mini helix motif”, known as the pre-miR, has an imperfect short stem
loop secondary structure with a 2-3 nt 3′ overhang. The pre-miR is then exported out of the
nucleus by the nuclear export machinery, which includes exportin-5 (XPO5) and a guanine
triphosphate (GTP)-bound form of the small nuclear guanine triphosphatase (RanGTP).
The XPO5/RanGTP complex contains a tunnel-like structure composed of two alpha helices
that interacts with the 3′ overhang of the pre-miR via hydrogen bonds and salt bridges, and
protects the pre-miR stem from hydrolysis by nucleases.113 Once bound, the pre-miR is then
transported out of the nucleus through the nuclear pore into the cytoplasm. The pre-miR is
then released from the XPO5/RanGTP complex via GTP hydrolysis.113
I.4.2 Cytoplasmic Processing
Once in the cytoplasm, the pre-miR is further processed by a protein complex containing
the cytoplasmic RNase III enzyme, Dicer, which removes the loop structure from the pre-
miR to generate∼22 nt double stranded RNA. The strands then separate, one strand, the
passenger strand, is degraded while the second strand known as the guide strand forms the
mature miRNA and is loaded into the Argonaute protein (AGO) containing miRNA-induced
silencing complex (miRISC) along with a complementary target gene mRNA.114 The miRNA
is termed either the 5p or the 3p miRNA according to which pre-miR strand (5′ or 3′) it
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originates. miR-137 is located on the 3p strand as shown in Figure I.3. Because the mature
miR-137 is located on the 3p strand, the seed sequence will be determined by the processing
of Dicer when it cleaves the apical loop, making biogenesis of miR-137 Dicer dependent.
I.4.3 MicroRNA Processing Associations with SZ
Microprocessing efficiency of pri-miRs is highly variable and has been shown to be a
better predictor of miR abundance than primary transcription.115 The typical micropro-
cessing of miR-137 was found to be inefficient, indicating low abundance.115 Postmortem
brain studies have found an association with increased primary miR processing in SZ pa-
tients corresponding to increased expression of the microprocessing components DGCR8 and
DROSHA and Dicer.116–118 These findings support a potential gain-of-function miR-137 risk
model in SZ.
I.4.4 Mechanism of miRNA Action
The miRISC guides the mature miRNA to the 3′ untranslated region (3′ UTR) of target
mRNAs and based on complementarity either results in translational repression or degra-
dation of the mRNA via the RISC machinery. Complementarity arises from a seed region
spanning the 5′ end of the miRNA. With perfect complementarity between the miRNA and
the seed region the AGO2 endonuclease activity is in close enough proximity to cleave the
mRNA strand which is then quickly degraded by exonuclease activity. With imperfect com-
plementarity the miRISC is able to recruit additional proteins to repress translation of the
target mRNA.
I.5 MicroRNA-137 Regulation and Function
I.5.1 Epigenetic Regulation
The DNA binding protein methyl-CpG-binding protein 2 (MECP2) was shown to me-
diate miR-137, involving coregulation by SOX2 in mouse adult neural stem cells (aNSC).119
Additionally, miR-137 was shown to repress Ezh2, a histone methyltransferase and polycomb
group protein, resulting in a global decrease in histone H3 trimethyl lysine 27.119 MECP2 is
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critical for brain development.120 DNA features alone can predict in vivo MECP2 binding
with high accuracy in part due to MECP2’s affinity to GC-rich chromatin.121 This is relevant
for miR-137 as it is located within a GC-rich region. Epigenetic regulation of miR-137 was
first characterized in cancer. miR-137 is a known tumor-suppressor and down-regulation
of miR-137 through methylation of the promotor region is associated with several cancers
including neuroblastoma.122–124
I.5.2 Nearby Variable Number of Tandem Repeats
One common variant found within the MIR137HG gene that is known to alter miR-
137 function is an exonic variable number of tandem repeats (VNTR) element found within
the pri-miR-137 transcript six bases upstream of the pre-miR sequence. This VNTR is a
repeating sequence of 15 bases, with three repeats being the shortest known length as well
as the major allele length. Findings regarding the VNTR can be found in Table I.3.122,125–128
This VNTR was first linked to altered mature miR-137 expression in melanoma cell lines.122
This and other in vitro studies show that longer VNTR lengths are associated with reduced
mature miR-137 expression.126,128 Variations in length of this VNTR have also been shown
to affect Stroop test performance in healthy controls.127 However, to date the relationship
between the VNTR length and risk for SZ is not known.
I.5.3 Role in Stem Cell Differentiation and Proliferation
In situ hybridization experiments with mouse embryonic stem cells showed that miR-137
is highly expressed in cells at all stages of mitosis and nearly undetectable in G1, S, and
G2 phase cells129 indicating that miR-137 is involved in cell division. This suggests that
miR-137 is expressed in a cell cycle-dependent manner in embryonic stem cells.129
In human embryonic stem cells (ESCs) MIR137HG was shown to be occupied by tran-
scription factors OCT4, SOX2, and NANOG which have essential roles in early development
and are required for the propagation of undifferentiated ESCs, indicating that miR-137 may
play a role in the regulatory circuitry of human ESC.130
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Table I.3: Previous Findings for the Variable Number Tandem Repeat Element
Allele Frequency
Repeats A B C D Associated with: Sample/Population Reference
3 72% 77.07% ND ND Major allele Control/SZ patients Mamdani et al.,2013
Control subjects, Sweden Strazisar et al.,2014
4 9% 12.35% 74.16% 78%





Predicted to alter pre-miR structure vs 3 repeats Strazisar et al.,2014
Lower miR-137 levels vs 3 repeats SH-SY5Y cells Strazisar et al.,2014
5 <5% 4.61% 6.18% 8.30%
6 <5% 2.47% 9.55% 4.80%
7 <5% 1.64% 1.69% 4.10%
8 <5% 0.65% 2.81% 2.40% More frequently found in SCZ Control/SZ patients Strazisar et al.,2014
patients than in control subjects
Predicted to alter pre-miR structure vs 3 repeats Strazisar et al.,2014
Lower miR-137 levels relative to 3 repeats SH-SY5Y cells Strazisar et al.,2014
9 6% 1.20% 1.69% 1.70% Lower miR-137 levels relative to 3 repeats HEK293 cells Mamdani et al.,2013
10 <5% ND 2.81% 0.70%
11 ND ND 0.56% ND
12 ND ND 0.56% ND Lower pri-miR-137 processing A375 cells Bemis et al.,2008
and miR-137 levels relative to 3 repeats
May differentially impact gene SH-SY5Y cells Warburton et al.,2015
transcription relative to 4 repeats
13 <5% ND ND ND Lower miR-137 levels relative to 3 repeats HEK293 cells Mamdani et al.,2013
Allele Frequency References: A-Mamdani et al.,2013; B-Strazisar et al.,2014; C-Warburton et al.,2015; D-Gonzalez-Giraldo et al., 2016
ND-not detected,SZ-schizophrenia
References A and B report the 3 repeat allele as the major allele, references C and D report the 4 repeat as the major allele.
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A miR-137 over-expression study in the human neural progenitor cell line CTXOE03
found that genes that were significantly down-regulated were enriched for involvement in
neuronal differentiation and included many GWAS associated genes.92
Most studies show overexpression of miR-137 is associated with increased differentia-
tion and decreased proliferation in ESCs.129,131,132 However one study showed the opposite
pattern with overexpression of miR-137 in mouse brain-derived aNSC associated with in-
creased proliferation, and reduction of miR-137 increasing aNSC differentiation.119 These
differential functional consequences demonstrate that regulation of stem cell differentiation
and proliferation by miR-137 may be cell context-dependent.
I.5.4 Role in Neuronal Maturation and Synaptic Morphology and Signaling
Overexpression of miR-137 inhibits dendritic morphogenesis, phenotypic maturation,
spine development and synaptic functions both in vitro and in vivo.133 Transfection of
miR-137 into mouse aNSC induced distinct morphological changes; cells were rounded or
trapezoidal in appearance with no neuritic outgrowth.131 Overexpression of miR-137 in
the neuroprogenitor cell line RenCell-VM and subsequent RNA-sequencing found significant
downregulation of transcription factors at 24 hours and up-regulation of SZ relevant pathways
at 48 hours. Pathways included calcium channels, synaptic proteins, FMRP-interacting
RNAs, and MHC genes.134 These results demonstrate that miR-137 acts as a network hub
by regulating transcription factors and their downstream pathways.
Decreased miR-137 expression promotes synapse formation and function. Down-regulation
of miR-137 in the neuroblastoma cell line SH-SY5Y led to altered expression of genes involved
in synaptogenesis and synaptic transmission.126 Inhibition of miR-137 increased target pro-
tein levels, increased number of vesicles at a distance of 50-200 nm from the synaptic release
site, and increased long-term potentiation (LTP).85 Similar results were found in a recent in
vitro study of mouse hippocampal neurons.135 Cheng et al. produced a miR-137 conditional
nervous system knockout mouse and found evidence of synapse overgrowth in both hippocam-
pal and cortical tissues upon loss of miR-137.136 Additionally, conditional knockout mice
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had significantly increased spine densities of basal and apical spines in the hippocampal CA1
region, indicating synaptic pruning deficits. Neurons of conditional knockout mice exhib-
ited increased dendritic complexity and enhanced dendritic growth compared to littermate
controls. These findings support a gain-of-function pathology in SZ and a loss-of-function
pathology in decreased expression in ASD.
miR-137 is involved in synaptic signaling through the regulation of LTP and long-term
depression (LTD), which are activity dependent enduring changes in synaptic strength. LTP
is a persistent enhancement of synaptic transmission; LTD is the complementary process
where synaptic transmission is reduced a phenotype that is also seen in SZ.137,138 The initial
mechanism in which miR-137 regulates neuronal signaling is by targeting proteins involved
in the release of neurotransmitters from the axon terminal.85 In neurons, cell-to-cell com-
munication is accomplished through chemical and electrical signals. In response to an action
potential, neurotransmitters are packaged into presynaptic vesicles within the axon terminal
and released into the synaptic cleft, where they bind to receptors on the postsynaptic neuron.
Several mRNAs for genes with well-known roles in presynaptic vesicle trafficking are vali-
dated targets of miR-137 including: complexin-1 (Cplx1), N -ethylmaleimide-sensitive fusion
protein (Nsf), synapsin-3 (Syn3), synaptotagmin-1 (Syt1).85 Overexpression of miR-137 in
vivo in the dentate gyrus of adult mice significantly reduced these target proteins as well
as the number of vesicles within the mossy fiber presynaptic terminals, and the number of
vesicles at a distance of 50-200 nm from the synaptic release site and increased vesicle num-
bers at 350-450 nm from the synaptic release site with no difference in the overall number of
vesicles.85 Additionally, overexpression was associated with a decrease in synaptic response
of the mossy fiber synapse and less LTP. Altered presynaptic vesicle trafficking resulted in
a reduced number of active synapses and defects in active synapses.85
Studies have also demonstrated that miR-137 regulates postsynaptic signaling through
a number of pathways thought to contribute to SZ including glutamatergic, GABAergic,
dopaminergic, and calcium channel signaling as well as many downstream pathways. The
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NMDA receptor subunit GluN2A is a miR-137 target and synthesis of GluN2A is inhibited in
the neural crest derived cell line PC12.139 Knockout of miR-137 in Drosophila demonstrated
that miR-137 regulates levels of NMDAR2, the homologue of the mammalian GluN2A pro-
tein, as well as GABA and dopamine receptors.140 Another glutamatergic miR-137 target
is the AMPA receptor subunit GluA1.81,141 Experiments with rat primary neuronal cultures
demonstrated that activation of metabotropic glutamate receptor 5 (mGluR5) transiently
upregulates miR-137. miR-137 represses AMPA-receptor mediated synaptic transmission
and is required for mGluR5 mediated LTD.141 The Drosophila miR-137 ortholog miR-1000
is expressed in presynaptic motor neurons and knockout in flies resulted in an increase in
the number and size of synaptic boutons and an increase in excitatory synaptic transmission
at the neuromuscular junction.142 Defects in mutant flies were due to glutamate excitotox-
icity due to overexpression of the vesicular glutamate transporter (VGlut). Experiments in
the Drosophila visual system determined that miR-1000 expression regulates VGlut in an
activity-dependent manner.142 In vitro and in vivo experiments by the same group showed
that this regulatory relationship is conserved in mice with miR-137 overexpression in the
dentate gyrus region of the hippocampus leading to elevated VGluT2 the VGlut ortholog.142
The ability of miR-137 to regulate multiple mRNAs involved in glutamatergic signaling sug-
gests that aberrant miR-137 function may contribute to glutamatergic signaling deficits in
SZ patients. The ion channel CACNA1C subunit Cav1.2 is also a miR-137 target.68 Multiple
GWAS have found independent associations with CACNA1C and SZ.22,23,38,67 This provides
another avenue that miR-137 may contribute to SZ phenotypes, although more research is
needed. Many intracellular pathways that are linked to SZ downstream of receptor activation
include miR-137 targets. Inhibition of miR-137 in mouse primary hippocampal neurons has
been shown to disrupt neuregultin 1α (Nrg1α) and brain derived neurotrophic factor (BDNF)
both of which have been linked to psychiatric disorders including SZ.81,143,144 Downstream of
Nrg1α and BDNF, miR-137 was found to regulate key proteins within the PI3K-Akt-mTOR
pathway including: the PI3K regulatory subunit p55γ, PTEN, Akt2, GSK3β, rictor and
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mTOR.81 The PI3K-Akt-mTOR pathway plays a critical role in multiple aspects of neu-
rodevelopment and neuronal function and defects in PI3K-Akt-mTOR signaling have been
linked to intellectual disability, ASD and SZ.145–147
Taken together, this large body of research suggests that miR-137 is a central regula-
tory molecule in many synaptic pathways that are independently associated with SZ and
disruption of miR-137 expression would have wide reaching effects on neurodevelopment,
neuroplasticity which may contribute to SZ pathology.
I.5.5 Animal Models
Animal models of miR-137 have been studied in mouse, fly and fish. Knockout of the
miR-137 ortholog miR-1000 in Drosophila led to a modest reduction in survival during
embryonic stages and a sharply reduced adult lifespan.142 Mutant flies also displayed glu-
tamate excitotoxicity, resulting in early-onset neurodegeneration and a movement disorder.
Results determined that the defects in the miR-1000 knockout flies was due to overexpres-
sion of the miR-1000 target gene VGlut. VGlut functions to load the predominant excitatory
neurotransmitter glutamate into synaptic vesicles of the Drosophila CNS. In zebrafish over-
expression of miR-137 was not associated with any observable phenotype.74 Downregulation
of miR-137 however, resulted in premature death and significant impairment of both embry-
onic and larval touch-sensitivity without compromising overall anatomical development.74
Several mouse models were used to study the impacts of altered miR-137 expression. Com-
plete whole body knockout of Mir137 in a mouse model led to embryonic lethality sometime
between E4.5 and E11.5.148 Mature miR-137 levels were not significantly different between
heterozygous and wild-type animals, suggesting compensation or decreased degradation of
miR-137. Additionally, there were no significant behavioral or cognitive differences found
between heterozygous and wild-type animals. Lentiviral-mediated overexpression in the
dentate gyrus of adult mice resulted in a deficit in hippocampus-dependent learning and
memory.85 A recent study by Cheng et al.(2018) established a germline global knockout
and a conditional nervous system knockout mouse model. Results showed complete loss of
27
miR-137 in either model lead to postnatal lethality in mice, which survived up to postnatal
day 21.136 These results underscore the critical role that miR-137 plays in neurodevelop-
ment. Similar postnatal lethality in both knockout groups suggests that the phenotypes in
the global knockout mice result from the loss of miR-137 in the nervous system. Knockout
mice were similar in terms of size and weight to controls at the early postnatal stage (P0),
but significant decreases in body and brain weights were observed in knockout mice as early
as P7, suggesting a postnatal effect of miR-137 loss-of-function. At P14 the major organs
of knockout mice including, heart, liver, lungs, and kidneys were significantly smaller than
littermate controls. Partial loss of miR-137 in heterozygous global and conditional knockout
mice did not result in survival or morphological differences. Both global and conditional
knockout mice displayed deficits in hippocampal-dependent learning and memory. resulted
in dysregulated synaptic plasticity, repetitive behavior, and impaired learning and social
behavior.136 Learning and memory deficits were seen in both overexpression and knockout
mouse models indicating that miR-137 mediated regulation could be dosage-dependent.85,136
I.5.6 MicroRNA-137 Gain-of-Function in Schizophrenia
There are two hypotheses for miR-137 expression as it pertains to risk for SZ. The loss
of function hypothesis for SZ is based on findings that the MIR137HG risk alleles have been
associated with decreased miR-137 expression in post-mortem brain from control individuals,
human fibroblast-derived neurons from controls, and patient hiPSCs. However it is notable
that post-mortem results in DLPFC showed relatively high miR-137 expression for both
risk and minor genotypes in patients, but significantly decreased expression in major allele
carriers only in the control group.80 Additionally postmortem brain studies found increases in
microRNA processing genes (DROSHA, DGCR8, and Dicer) in patients which corresponded
to significant increases in mature miR levels.117,118 These findings suggest an aberrant gain-
of function pathology in SZ patients. Both in vitro and in vivo miR-137 overexpression
models are more consistent with SZ phenotypes. One study with a seemingly contradicting
result examined hiPSC from patients and found an increase in miR-137 expression when
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SNP rs1198588 was “corrected” via CRISPR from the major risk genotype to the minor
genotype.87 Our data indicate that there are multiple risk factors within the region with
a rare high risk contribrution for the rs1198588 minor allele(Chapter III). Epistatic risk
interaction would underlie risk association to both rs1198588 alleles. Taken together these
results support a model of miR-137 overexpression in SZ.
I.5.7 Role in Other Neurological Disorders
I.5.7.1 Major depression
Patients with depressed suicidal behavior were found to have downregulated expression of
miR-137 in prefrontal cortex compared to controls.149 A post-stroke depression mouse model
found significantly lower miR-137 in brain and peripheral blood; these behavioral changes
were improved through upregulation of miR-137.139 Additionally, a risk allele within miR-
137 target gene CACNA1C has been associated with risk for major depression as well as SZ
and BD.150–152
I.5.7.2 Huntington’s Disease
HD is a neurodegenerative disorder presenting with motor dysfunction, cognitive decline
and psychiatric symptoms caused by CAG repeat expansion in the huntingtin gene (HTT ).153
Repressor Element-1 Silencing Transcription Factor (REST) is a repressor whose cytoplasmic
association with HTT is disrupted in HD, resulting in an increase in nuclear REST.154
REST is known to regulate miR transcription including miR-137 which is up-regulated with
REST knock-down.155 This result indicates that disrupted regulation of miR-137 by REST
contributes to HD pathology.
I.5.7.3 Autism Spectrum Disorder: Diametric MIR137HG Risk Variants
Several ASD associated genes are confirmed or putative targets of miR-137.156–158 While
SZ and ASD share a subset of phenotypes and risk variants, there are several known patho-
logical variants and pathways in which the direction of risk for SZ is the opposite of risk
direction for ASD, also known as the diametric hypothesis.159,160 The MIR137HG locus
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follows this diametric pattern of association. Findings from GWAS have identified minor
allele SNPs within the MIR137HG locus to be associated with ASD, which is the opposite
finding for GWAS SZ SNPs which are all major alleles.161 Conditional knockout of miR-137
in mice lead to social deficits and unusual repetitive behavior, phenotypes that are associated
with ASD.136 Individuals with microdeletion of MIR137HG had a syndrome presenting with
intellectual disability, ASD, and obesity.20,78,162–164 Eleven out of 12 patients with this hem-
izygous deletion were diagnosed with ASD. Some of these deletions overlap with the nearby
dihydropyrimidine dehydrogenase gene (DPYD), deficiency of which is associated with a
childhood onset neurological disease. However, studies have shown that loss of MIR137HG
alone is sufficient to produce all three features of the syndrome (ASD, intellectual disabil-
ity, and obesity).162,164 Rett syndrome is an autism-spectrum neurodevelopmental disorder
caused by loss-of-function mutations in the gene encoding MECP2. Patients with Rett
syndrome acquire severe neurological symptoms including breathing irregularities, ataxia,
seizures, autistic traits, and mental retardation.165 MECP2 regulates gene expression by
DNA methylation via recruitment of histone deacetylases. Studies have shown that MECP2
represses miR-137 expression in vitro and in vivo which contributes to Rett syndrome phe-
notypes.119,166,167 These findings support a role for miR-137 loss-of-function variants in ASD,
which is opposite to the previously described gain-of-function variants associated with SZ.
I.5.8 Understanding Molecular Mechanisms Underlying MIR137HG
Associations with Schizophrenia
Despite many findings supporting the role for dysregulated miR-137 function in SZ, the
specific molecular mechanisms responsible for risk remain unknown. In the present body
of research, we investigate how MIR137HG common genetic variants contribute to risk for
diagnosis, through examination of their contribution to pri-miR-137 transcriptional variation.
The main objectives for this study were (i) to characterize the transcription of theMIR137HG
gene at both early and late developmental time points through cloning and sequencing of
commercial human brain tissues, (ii) to evaluate how common genetic variants including the
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VNTR and GWAS SNPs contribute to risk for SZ and transcriptional variation and (iii)
to evaluate how epigenetic regulation of the region may affect transcript variant expression.
This research is the first to demonstrate alternative splicing of miR-137 and characterize
multiple genetic risk factors within the MIR137HG region. We provide novel molecular
mechanisms of miR-137 regulation which would be important for brain development and
potentially contribute to the etiology of SZ.
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CHAPTER II
NOVEL PRI-MIR-137 TRANSCRIPT VARIANTS ARE ASSOCIATED
WITH VNTR GENOTYPE AND DEVELOPMENTAL STAGE
II.1 Introduction
Schizophrenia (SZ) is a neurodevelopmental disorder with complex etiology. Over 100
genetic loci are associated through genome wide association studies (GWAS) with adult
onset schizophrenia (AOS).23,38,39,70 The microRNA-137 (miR-137) gene (MIR137HG) is a
top association in these studies with multiple SNPs reaching genome wide significance within
the gene locus. MicroRNAs are small non-coding RNAs which downregulate the expression
of target genes by binding to mRNA and either targeting transcripts for degradation or
preventing translation. Convergent evidence from genetic, phenotypic, and functional studies
support the association of miR-137 with SZ. There is significant overlap between miR-137
target genes and genes associated with SZ.38,68,70,95,168 miR-137 has been shown to act as
a gene network hub during synaptic development, functioning upstream in many critical
neurodevelopmental pathways that are independently associated with SZ such as Nrg/ErbB,
PI3K-Akt-mTOR, and MAPK/ERK signaling.80,81,141 Functionally, miR-137 regulates adult
neurogenesis, synaptic plasticity, and synaptic signaling, all processes thought to contribute
to the pathobiology of SZ.85,92,141,168 Despite these numerous associations, specific molecular
mechanisms underlying miR-137’s role in SZ risk are unknown.
Subtle changes in miRNA regulation or function may have far reaching biological con-
sequences as a single miRNA can regulate expression of thousands of target genes, and
indeed miR-137 has over 1,300 predicted targets.104 It is critical to understand typical
transcriptional regulation of miR-137 to determine potential pathoetiology. miR-137 is pro-
cessed canonically through several stages, initially the primary miRNA (pri-miR-137) is
transcribed and cleaved into a short stem-loop precursor microRNA-137 (pre-miR-137) by
the DROSHA/DGCR8 complex. The pre-miR-137 transcript is then exported out of the
nucleus and cleaved a second time by Dicer to become the final mature miR-137 strand. We
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hypothesize that transcriptional variation at the pri-miR-137 level may contribute to risk for
SZ. The main goal of this research is to thoroughly characterize pri-miR-137 transcripts in
human brain using an exon walking PCR methodology in addition to cloning and sequencing
in commercial total brain RNA tissues.
Additionally, sequencing allowed us to evaluate associations with a nearby variable num-
ber of tandem repeats (VNTR) element. The VNTR is located within the pri-miR-137 tran-
script six bases upstream of the pre-miR-137 sequence. This VNTR is a sequence of 15
bases with high GC% content repeated. Three repeats (3R) is the shortest known length in
humans and the common allele. In vitro studies show that mature miR-137 expression is
affected by the length of this VNTR where greater lengths are associated with lower expres-
sion.128 Variations in VNTR length have also been shown to affect Stroop test performance
in healthy controls.127 A secondary goal of this study is to evaluate the relationship between
VNTR length and pri-miR-137 transcript variants. Determining how common genetic vari-
ants such as this VNTR correlate with altered transcription and processing of miR-137 is a
critical step in establishing miR-137’s contributions to the etiology of SZ.
II.2 Methods and Materials
II.2.1 PCR
To investigate pri-miR-137 transcription and splicing in human brain we used custom
PCR primers to capture known exons (Figure II.1) in commercial brain tissues. The pri-
miR-137 (UCSC ID uc001drx.2) transcript contains 5 exons and 4 introns. Primer pairs
(Table II.1) were designed with a 5′ guanine (G) to facilitate cloning, and included a forward
primer for each of the 5 exons with a reverse primer in exon 5. Complimentary DNA
(cDNA) libraries were constructed using RNA from Human Fetal Brain Total RNA (Clontech
Cat# 636526) and adult Human Brain Total RNA (Ambion Cat# AM7962). These tissues
contain total human brain RNA pooled from multiple Caucasian individuals (fetal RNA:
n=21, 26-40 weeks gestational age, male/female ratio unavailable; adult RNA: n=23, 23-
86 years of age, 13/10 male/female). cDNA was synthesized using standard protocols for
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Custom Primers for Known pri-miR-137 Exons









Figure II.1: Blue boxes represent the five pri-miR-137 transcript exons. Red arrows represent
approximate PCR primer forward and reverse locations. Dashed red lines represent resulting
PCR products. Expected product sizes for each primer pair are listed on the left side of the
figure.
Table II.1: Pri-miR-137 PCR Primers for Cloning and Sequencing
Exon Primer Sequence
1 5’ GGACTCCTCGGAAGCATGAG 3’
2 5’ GGCACTCAATCATACCACCTAGAG 3’
3 5’ GAGCGGCCATTTGGATTTGG 3’
4 5’ GCCTCTGGGATGTGTTCTGA 3’
5 5’ GCCAGAAAAGAAGGAAGCCTGAA 3’
5Reverse 5’ GTGCCCTTCCTCAAGACAGTTTATG 3’
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the Oligo(dT) primed SuperScript R©III First-Strand Synthesis System. PCR was conducted
using standard protocols for PlatinumTMTaq DNA Polymerase High Fidelity (ThermoFisher
Cat# 11304029). Resulting PCR products were run on an agarose gel to verify correct
transcript sizes and visualize banding patterns.
II.2.2 Cloning
Cloning of PCR products was conducted using the TOPO R©TA Cloning R©Kit with
pCRTM2.1-TOPO R©vector and One Shot R©Chemically competent cells. Whole PCR prod-
ucts were used for cloning as attempts to isolate individual bands from gels were unsuccessful.
Initial cloning attempts yielded low cloning efficiency, most likely due to the exonuclease ac-
tivity of the PlatinumTMTaq DNA Polymerase High Fidelity. The pCRTM2.1-TOPO R©vector
has 3′ thymidine (T) overhangs that utilize the terminal transferase activity of Taq poly-
merase which adds a single deoxyadenosine (A) to the 3′ ends of PCR products. In order to
improve cloning efficiency, Platinum Taq DNA Polymerase, which has decreased exonuclease
activity, was used for 3′ A-tailing of PCR products. Cells were plated on either 50ug/ml
kanamycin or 100ug/ml ampicillin agar plates and blue and white screening was used to
select vector containing colonies. Colonies were then placed in a 100mg/ml ampicillin LB
broth starter culture overnight and then 1:500 dilutions were cultured for an additional 13-14
hours. Plasmid DNA was isolated using standard protocols for the QIAprep R©Spin Miniprep
kit.
II.2.3 Sequencing
Plasmid DNA was diluted to 50ng/ul for sequencing. Sequencing was conducted through
GENEWIZ R©using M13 forward and reverse primers. Sequences were aligned to the refer-
ence genome using NCBI BLAST R©169 and CodonCode Aligner software
(www.codoncode.com/aligner/index.htm). Sequencing allowed us to determine VNTR




Associations between spliced transcripts, developmental time points (fetal, adult) and
VNTR length were evaluated using Fisher’s exact test (FET). To evaluate associations be-
tween alternative splicing and transcript VNTR length, the VNTR was categorized as either
3R (major allele) or >3R (minor allele) based on genetic and biological findings regarding
the VNTR.127,128 The following associations were examined: splicing vs. developmental time
point, VNTR length vs. developmental time point, and VNTR length vs. splicing within
and between time points.
II.2.5 Transcript Secondary Structural Changes
To explore how the primary 5′ alternative splice sites may affect pre-miR-137 processing
we utilized the RNAfold WebServer (part of The Vienna RNA Websuite) to visualize the
splice sites in the context of pri-miR-137 secondary structure and critical cis-acting sequence
elements.170 The RNAfold WebServer predicts the optimal secondary structure using mini-
mum free energy prediction. The sequence from each splice site to 100 bases past the end of
exon three was used as the input and standard parameters were used.171
II.3 Results
II.3.1 PCR
Gel electrophoresis of PCR products showed the correct band size for all primer pairs
(Figure II.2a). A multiple banding pattern was seen for all pri-miR-137 reactions containing
exon 3 (E1-5, E2-5, E3-5) with smaller product bands seen just below the expected product
size, while single bands were seen for E4-5 and E5-5 reactions. This indicates alternative
splicing of expected transcripts within exon 3 (Figure II.2a). Further examination of the
banding pattern revealed potential expression differences between the fetal and adult tis-
sues with smaller transcripts displaying brighter banding in fetal cDNA, indicating higher
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Figure II.2: (a)PCR results are shown for pri-miR-137 custom primer pairs in adult and fetal
total brain cDNA. Exon primer pairs are labeled along the top of each gel lane (i.e. E1-5
is primer pair exon 1 to exon 5). Ladders and corresponding base sizes are shown on either
side. Results for both adult and fetal total brain tissues depict correct product lengths for
all primer pairs (E1-5:2034, E2-5:1797, E3-5:1694, E4-5:1307, E5-5:838). Multiple banding
patterns can be seen for all reactions containing exon 3, indicating alternative splicing within
exon 3. (b)A magnified view of PCR results for primer pair E3-5 in both fetal and adult
total brain displays brighter bands in the smaller alternatively spliced products of the fetal
brain. This suggests higher expression of alternative transcripts in the fetal brain sample.
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Table II.2: Cloning and Sequencing Transcript Data
Adult Brain Fetal Brain
Variant (n=73) Freq.(%) (n=47) Freq.(%) FET p
SS’ 18 24.7 30 63.8
SS” 1 1.4 3 6.4
Total SS 19 26.0 33 70.2 8.30e-06
VNTR
Length (n=73) (n=56)
3 66 90.4 30 53.6
4 1 1.4 20 35.7
5 0 0.0 2 3.6
6 0 0.0 2 3.6
7 5 6.8 2 3.6
9 1 1.4 0 0.0
Total >3 7 9.6 26 46.4 5.40e-06
SS - Splice site, SS’ - primary, SS” - secondary
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Figure II.3: Canonical splicing of pri-miR-137 exons 3-5 is indicated by dashed lines on top of the region. Dashed lines on the
underside of the region indicate alternative 5′ splicing of exon 3 from the alternative splice site (SS) to either exon 4 or 5. Arrows
point to resulting canonical and del-miR-137 transcript isoforms. Del-miR-137 transcripts exclude the majority of pre-miR-137
sequence including the mature miR-137 sequence. Expression of these transcript isoforms provides a novel regulatory mechanism
for mature miR-137.
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II.3.2 Cloning and Sequencing
Cloning and sequencing allowed us to characterize pri-miR-137 transcript isoforms. Fifty-
six total transcripts were assessed from fetal brain, 78 total transcripts were assessed from
adult brain (Table II.2). Two novel splice sites were found, termed the primary (SS′) and
secondary (SS′′) splice sites due to their frequency. The SS′ was found in 91% (30/33)
of fetal spliced transcripts and 95% (n=18/19) of adult spliced transcripts, the remainder
were spliced at SS′′. The location of both splice sites is within the pre-miR-137 sequence,
upstream of the mature miR-137 sequence (Figure II.3). Importantly, the resulting spliced
transcripts are missing the mature miR-137 sequence and are thus termed deleted-miR-137
(del-miR-137) transcripts. Expression of del-miR-137 transcripts may indicate a previously
unknown regulatory mechanism for miR-137.
Direct sequencing of the transcripts allowed us to evaluate VNTR length proportions
between developmental groups and associations with alternative splicing. All transcripts
containing the VNTR were included in allele frequency analysis (adult n=73, fetal n=56).
The VNTR allele frequency between fetal and adult groups was significantly different with
a higher proportion of transcripts containing minor (>3R) VNTR lengths in the fetal
group(FET p=5.919e-06)(Table II.2, Figure II.4). These differences are thought to reflect
population sampling differences in genotype between age groups and not developmental reg-
ulation, as VNTR length would not change across development.
Next, the frequency of spliced transcripts was evaluated. All transcripts that spanned
the splice sites (fetal 47/56, adult 73/78) were included in the frequency analysis. The
proportion of spliced transcripts was significantly higher (FET p=2.145e-06) in the fetal
brain group(70%) compared to the adult group(26%)(Table II.2). We suspect this finding
may be in part due to the VNTR length association with splicing frequency as discussed
subsequently (Table II.2) in addition to developmental regulation. Importantly, we found
significant positive associations between VNTR length and proportions of spliced transcripts.
In both age groups transcripts containing VNTR lengths >3R were primarily del-miR-137
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Transcript VNTR Repeat Lengths
Adult Brain (n=73) Fetal Brain (n=56)
***
Minor Allele Proportions 
Figure II.4: Significant differences are seen in transcript proportions of VNTR alleles. Adult
brain transcripts had a significantly higher proportion of the major VNTR allele length
of 3 repeats(Fisher’s p=5.4e-06). Adult transcripts had a VNTR minor allele frequency
(MAF) frequency of 9.6%, which is significantly lower than the VNTR MAF of fetal brain
transcripts, 46.4%. The ‘Minor Allele Proportions’ section shows the distribution of repeat
lengths within the ‘Total >3’ category. These differences are thought to reflect population
sampling differences between age groups.
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Figure II.5: Frequency of spliced transcripts or del-miR-137 transcripts are depicted for both
fetal and adult groups, and then the combined allele length groups. There is a significant
positive association between VNTR length and splicing frequency in all three (Adult, Fetal,
Combined) groups. Interestingly, there is also a significant difference between splicing of
the 3R transcripts and developmental group. A higher frequency of 3R transcripts were
spliced than in the adult group. This indicates a potential epigenetic component underlying
alternative splicing and that it is neurodevelopmentally regulated.
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transcripts (FET p=0.029 fetal, p=3.093e-05 adult, p=7.098e-09 combined)(Figure II.5).
Significant association between VNTR length and spliced transcripts would contribute to
overall differences in proportions of spliced transcripts between age groups as there are
significant differences in VNTR allele frequencies between groups. These results implicate
VNTR length genotype may contribute to alternative splicing of the pri-miR-137.
Additionally, the splicing of the major VNTR allele (3R) was significantly different
between fetal and adult groups (FET p=6.790e-04). We predict that this reflects develop-
mental differences in epigenetic regulation of the region, independent of VNTR length as
VNTR genotype is consistent between groups. Due to high LD (r2>0.8) spanning the region
(Figure I.1), GWAS risk SNPs may be tagging the VNTR. Further analysis of the VNTR
and SNP LD structure will be needed. These results implicate VNTR length in conjunction
with epigenetic factors as regulators of miR-137 through a novel pri-miR-137 alternative
splicing mechanism. Aberrant alternative splicing of pri-miR-137 may present a previously
unknown mechanism contributing to risk for SZ.
II.3.3 Del-miR Transcript Biogenesis and Secondary Structural Changes
To verify that del-miR-137 transcripts are the result of alternative splicing and not
co-transcriptional microprocessing, the location of the splice sites was mapped to the sec-
ondary pri-miR-137 structure with red arrow heads indicating DROSHA cleavage sites (Fig-
ure II.6(a)). Splice site locations indicated by orange arrows are inconsistent with miRNA
co-transcriptional processing as the SS′′ is located 21 bases upstream of the 5′ DROSHA
cleavage site, while the SS′ is 4 bases downstream of the 5′ DROSHA cleavage site. Addi-
tionally, splice site sequence elements are consistent with canonical splicing with a 5′ splice
donor site ‘GU’ sequence underlined in Figure II.6a. These results show that del-miR-137
transcripts are likely the result of the canonical splicing pathway and not due to processing
by the DROSHA/DGCR8 complex.
Alternative splicing of the pri-miR-137 and expression of del-miR-137 can not be assumed
to ablate expression of the mature miR-137 as miRs can still be processed from spliced
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Alternative Splicing Effects on Pri-miR-137 Secondary Structure
SS’’ SS’
Figure II.6: Secondary structure for the canonically processed pre-miR-137 is depicted on top. The bottom left structure is
the predicted result of the secondary splice site. All critical processing sequences are still in tact, therefore the excised RNA
from the secondary spliced del-mir-137 would still have the potential to be processed by DROSHA/DGCR8 and produce a
functional mature miR-137. The predicted structure of the excised RNA from the primary splice site is shown on the bottom
right. Structure of the cis-acting sequence elements would not allow binding of the DGCR8/DROSHA microprocessor and
would therefore decrease processing efficiency and mature miR-137 expression.
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sequence such as introns. However, secondary structure and processing motifs of the pri-
miRs are still critical for proper cleavage of intronic miRs by the microprocessor complex.172
Important cis-acting sequence motifs include a basal ‘UG’ motif, an apical ‘UGU’ motif, a
lower stem ‘GHG’ motif, and a 3′ tail ‘CNNC’ motif.112 Secondary structure analysis allowed
us to visualize the spliced portion of del-miR-137 containing the miR-137 in the context of
pri-miR-137 sequence motifs and structural changes in order to determine if pre-miR-137
may still be successfully processed. Predicted structure for the spliced portion of del-miR-
137 is depicted in Figure II.6(b) with critical processing motifs highlighted. Of note, miR
databases have indicated that the ‘CNNC’ motif for pri-miR-137 is the ‘CGGC’ sequence just
downstream of the highlighted ‘CAGC’ sequence. However, the 100 vertebrate conservation
track in UCSC shows the ‘CAGC’ motif as being more highly conserved and the secondary
structure would allow more binding access to the ‘CAGC’ motif suggesting the ‘CAGC’
motif is primarily utilized in pre-miR-137 processing.173 Results show that the stem loop
structure of the spliced sequence containing the mature miR-137 would be preserved when
the SS′′ is used and has the potential to be recognized and cleaved by the microprocessor
complex. In contrast, if the SS′ is utilized, the stem loop structure would be disrupted and is
missing the basal ‘UG’ motif and the 5′ DROSHA cleavage site. This structure also disrupts
the structure of the ‘CAGC’ and ‘GAG’ motifs, which are critical for DROSHA cleavage.
These results indicate that processing by the DROSHA/DGCR8 complex would be reduced
or prevented by splicing and expression of the del-miR-137 transcript.
An alternative miRs biogenesis pathway which substitutes DROSHA cleavage with splic-
ing is described for a subgroup of miRs known as ‘mirtrons’. The mirtron pathway bipasses
DROSHA processing through splicing followed by incorporation of the pre-miR sequence into
the intron lariat. The lariat is then debranched by lariat debranching enzyme, folded into
a pre-miR hairpin, and intronic tails are trimmed by an exonuclease.174 The pre-miR-137
could still be generated from the mirtron pathway and would form a 3′-tailed mirtron that
would then follow the canonical miR biogenesis pathway being exported out of the nucleus
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and cleaved by Dicer.174 However, the mirtron pathway generates substantially fewer mature
reads relative to canonical miR biogenesis. Taken together, these findings provide evidence
for decreased processing efficiency of pre-miR-137 and subsequent downregulation of mature
miR-137 expression through the alternative splicing of del-miR-137. Expression of del-miR-
137 transcripts provides an alternative regulatory method for the mature miR sequence of
this critical microRNA.
II.4 Discussion
Schizophrenia’s underlying pathoetiology is extremely complex. Previous genetic and
clinical evidence provides a compelling case for the role of miR-137 in disease risk, as well as a
role for the VNTR in miR-137 regulation. However, an underlying molecular risk mechanism
has not been identified. Through cloning and sequencing we characterized transcriptional
variation of the MIR137HG gene in human brain tissue at both early and late developmental
time points. We describe novel 5′ splice donor sites within exon 3 that cleave the pre-miR-
137 and generate novel del-miR-137 transcripts. Processing of this altered pre-miR-137 se-
quence is consistent with the canonical RNA splicing pathway rather than co-transcriptional
processing by the DROSHA/DGCR8 complex. The resulting lariat containing the partial
pre-miR-137 and the mature miR-137 could potentially be processed through the mirtron
pathway, however, this would significantly reduce processing efficiency. As processing ef-
ficiency is a better predictor of mature miR expression than primary transcription,115 we
conclude that mature miR-137 expression would be significantly downregulated with this
alternative processing pathway. This alternative splicing of the pri-miR-137 presents a novel
regulatory mechanism for miR-137, which may contribute to risk for SZ. As a pattern of
miR-137 overexpression is thought to contribute to SZ etiology, we predict that regulatory
pathways that decrease miR-137 expression, such as del-miR-137 splicing would be decreased
in patients.
Additionally, we found significant positive correlations between alternatively spliced
transcripts and VNTR length, as well as evidence of potential developmental splicing regu-
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lation. These findings illustrate the complex nature of SZ with both genetic and epigenetic
factors potentially playing a role in transcriptional regulation of MIR137HG . Longer VNTR
lengths were found significantly more within the del-miR-137 transcripts at both early and
late developmental time points indicating that the length of the VNTR sequence could affect
splicing and regulation of pri-miR transcripts consistently across development. The mecha-
nism behind this correlation is unknown, however the high GC% content of the VNTR hints
at DNA methylation or associated factors as potential regulators. DNA methylation has
previously been associated with alternative splicing through the DNA binding factors CTCF
and MECP2. Further analyses will be needed to elucidate how VNTR length contributes to
genetic risk architecture.
Another key finding is the significant differences in splicing of the 3R VNTR transcripts
between developmental groups. The fetal group had a significantly higher proportion of del-
miR-137 compared to the adult group, suggesting potential epigenetic regulation of alterna-
tive splicing across development. Again, the precise mechanism of regulation is unknown but
the high GC% content of the region implicates DNA methylation may be involved and would
be consistent with the VNTR findings. DNA methylation has previously been shown to be
negatively correlated with miR-137 expression.122 Furthermore, aberrant DNA methylation
has previously been associated with SZ diagnosis.59–61 Additional research will be needed
to determine how alternative splicing of pri-miR, VNTR length and epigenetic factors con-
tribute to the regional SZ risk association. Our findings reflect the complex nature of the
MIR137HG genomic region as well as the etiological architecture of SZ and provide a novel




HAPLOTYPE ASSOCIATIONS WITH DIAGNOSES PROVIDE INSIGHT
INTO THE GENETIC RISK ARCHITECTURE OF MIR137HG
III.1 Introduction
Evidence from genetic, clinical, and functional studies support the association of the
MIR137HG region with SZ.17,21 Common variants in the region have been associated with
altered miR-137 expression and function.80,85,87 One such variant is the exonic VNTR el-
ement located within the pri-miR-137 transcript six bases upstream of the pre-miR-137
sequence. The VNTR is a repetitive sequence of 15 bases, with high GC% content. Three
repeats is the shortest known length as well as the reported common allele in humans. Pre-
vious findings regarding the VNTR are summarized in Table I.3.122,125–128 Overall, greater
VNTR lengths are associated with decreased miR-137 expression. Our previous cloning and
sequencing results from total brain RNA support these findings (Chapter II). We discov-
ered novel transcripts containing increased VNTR lengths to be associated with alternative
splicing of the pri-miR-137 at both fetal and adult time points. Alternative splicing cleaves
the pre-miR-137 sequence and produces transcripts that have the mature miR-137 sequence
spliced out termed del-miR-137. Splicing is predicted to result in decreased processing ef-
ficiency and expression of the mature miR-137 (Chapter II). The mechanism of association
between the VNTR length and altered transcription of pri-miR is not currently known.
Genetic risk architecture of the region is still not well understood. Strazisar et al. showed
an association with the 8 repeat allele and SZ diagnosis.126 No other studies have shown
association with VNTR length and diagnosis despite associations with changes in miR-137
expression and cognitive phenotypes.127 In the present study, we evaluate the risk of the
VNTR in genomic context by including the VNTR and GWAS SNPs in a case-control hap-
lotype analysis. Haplotype analyses are more powered to detect associations relative to
individual variant associations when multiple causal variants are acting in cis,175 which pre-
vious evidence suggests is the case in the MIR137HG genome region.87,126 As the previous
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GWAS have demonstrated association between the common alleles in the region and dis-
ease, we use a robust GLM analysis method to evaluate risk with common haplotypes.175,176
Additionally, as there may be multiple causal variants in the region, haplotype analysis will
enable us to better detect rare haplotype associations.175 Our clinical cohort consisted of
307 healthy controls and 602 adult onset schizophrenia (AOS) patients.
Importantly, we include analysis of genotype and haplotype associations with a cohort
of 89 COS patients. COS is a rare form of SZ defined by an earlier age of onset before age
13.62 Previous research has determined COS to be a more genetically and phenotypically
severe form of SZ, associated with a higher rate of copy number variants in AOS associated
pathways as well as more severe morphological changes in the brain and a higher incidence of
prepsychotic developmental disorders.64,66,177–179 Evaluating genetic associations in multiple
phenotypic subpopulations including COS is important for understanding the pathobiology
of AOS and etiological differences between AOS and COS. Our COS cohort is one of only
two in the nation, underscoring the importance of evaluating genetic associations in this rare
phenotype.
III.2 Methods and Materials
III.2.1 Subjects
All study procedures were approved by the Colorado Multiple Institutional Review
Board, University of Colorado and samples collected in accordance with the Declaration
of Helsinki principles. All clinical subjects were drawn from individuals participating in
the Department of Psychiatry ‘Genetic Research in Schizophrenia’, part of a larger original
study of the Molecular Genetics of Schizophrenia Consortium, and as described previously.180
A consensus diagnosis of schizophrenia based on DSM-IIIR or DSM-IV criteria was made
following a systematic examination of multiple sources of available information obtained
from relatives, medical records, clinicians, and direct assessment using one or more diag-
nostic interviews including the Diagnostic Interview for Genetic Studies (DIGS), the Struc-
tured Clinical Interview for Axis I DSM Disorders (SCID). Control subjects were evaluated
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using the SCID-Non-patient Edition. COS subjects were recruited through the Colorado
Childhood-onset Schizophrenia Research Program at the University of Colorado School of
Medicine.181,182 Diagnosis of COS was made after the Schedule for Affective Disorders and
Schizophrenia for School-age Children - Present and Lifetime Version (KSADS- PL; Kauf-
man et al., 1997) was administered to one parent and the child. Criteria for diagnosis were
identical to those utilized in adult populations and as described previously.181,182 All sub-
jects in this study were unrelated to each other. Where postmortem brain DNA samples
were used these were obtained from the Schizophrenia Research Center Brain Bank at the
University of Colorado, School of Medicine, all of which were donated through the Colorado
Anatomical Gift Act. The Brain Bank contains tissue collected postmortem from subjects
with a diagnosis of SZ as well as from unaffected individuals.183 DNA was isolated using stan-
dard methods, from unrelated Caucasian individuals (AOS (n=602) COS subjects (n=89)
and control (n=307); See Table III.1 for demographics). Subjects were included for analyses
only if all variants were successfully genotyped.
III.2.2 Genotyping
III.2.3 GWAS SNPs
Three GWAS significant SNPs (rs1625579, rs1198588, rs2660304) were genotyped for all
individuals. All SNPs were in Hardy-Weinberg equilibrium in controls (rs1625579: χ2=0.275,
p=0.600; rs1198588: χ2=0.039, p=0.844; rs2660304: χ2=0.275, p=0.600). Genotyping was
performed in duplicate for each sample using TaqMan Genotyping Assays and qPCR on a
7900HT Fast Real-Time PCR System. Samples were excluded if genotype calls were unde-
termined or if discrepant calls were made between duplicates after two rounds of genotyping.
Sample sizes can be found in Table III.2. Multiple testing correction was not performed
as we considered this a replicative analysis of previous associations in schizophrenia;23,70,86
p-values of <0.05 were considered as statistically significant.
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Table III.1: Subject Demographics
Subjects N Mean Age* +/-SE No. (%) male
Controls 307 51.0+/-0.85 161 (52.4%)
COS 89 10.1+/-0.28 61 (68.5%)
AOS 602 42.2+/-0.53 421 (69.9%)
COS- childhood onset schizophrenia; AOS- adult onset schizophrenia
*Age at collection is given for samples from blood draws, age at death
is given for brain samples, age at first visit to clinic typically coinciding
with age of diagnosis is given for COS samples
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Table III.2: SNP and VNTR Genotype Distributions
Control COS AOS Combined
Location MAF MAF MAF MAF
Variant (HG19) Alleles* (n=307) (n=89) P OR(CI) (n=598) P OR(CI) (n=687) P OR(CI)
rs1198588 1:98552832 T/A 0.176 0.225 0.047
3.23
(1.15-8.96)
0.196 0.593 0.198 0.429
rs2660304 1:98512127 T/G 0.174 0.174 0.577 0.182 (n=601) 0.830 0.179 (n=690) 0.762
VNTR 1:98511734 3/>3 0.319 (n=306) 0.256 (n=88) 0.283 0.281 (n=590) 0.095 0.277 (n=678) 0.079
0.57
(0.34-0.96)


























An optimized PCR protocol for the VNTR was used to genotype all individuals with
custom primers (VNTR Forward: 5′ GCTCAGCGAGCAGCAAGAGT 3′; VNTR Reverse:
5′ GTCACCGAAGAGAGTCAGAGGACC 3′; VNTR Reverse 5′; FAM labeled: 5′ TCAC-
CGAAGAGAGTCAGAGGACC 3′) using the GC-RICH PCR System mfr. Roche, which
allowed for the amplification of extended length repeats. PCR products were run on a 3%
agarose gel to resolve the 15bp repeat size differences. After a sufficient number of samples
were run, a band size ladder was generated with VNTR lengths ranging from 3-12 repeats
(Figure III.1). Ladder results were confirmed through DNA Fragment analysis (GENEWIZ)
with a fluorescent FAM labeled primer. Manual calls were 100% consistent with fragment
analysis results. This ladder was used for comparison in order to genotype remaining indi-
viduals manually.
III.2.5 Statistical Analyses
The VNTR was nominally grouped as either 3 repeats (3R) or greater than 3 repeats
(>3R) based on previous expression and phenotype differences based on this grouping.127,128
Fisher’s exact test (FET) with mid-p correction was used to calculate ORs and confidence
intervals (CIs).
III.2.6 SNP/VNTR Genotypes Grouped vs Diagnosis
A preliminary investigation of the VNTR’s contribution to risk was conducted via Pear-
son’s Chi-square by grouping individuals into three categories: homozygous risk SNP back-
ground for all GWAS SNPs/homozygous for the 3 repeat VNTR (11,11,11,2), homozygous
risk SNP background for all GWAS SNPs/either heterozygous or homozygous for longer
VNTR repeats (11,11,11,1 or 0), and all other haplotype combinations (ELSE). Analyses
were conducted for AOS vs. Controls, COS vs. Controls and AOS/COS combined diagnosis
vs. Controls.
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VNTR Ladder Used for Manual Genotyping
3,3  3,4      3,5   3,6       6,7   3,7       3,9   3,9    9,10   3,10    4,11  3,12
Figure III.1: After a sufficient number of samples were run to see a range of genotypes, a
genotype ladder was generated. Each lane is an individual, with VNTR genotype listed below
PCR bands. Genotype sizes were verified through fragment analysis. VNTR genotypes are
depicted below each sample lane. The ladder was used to manually genotype subsequent
samples.
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III.2.7 Haplotype Analyses Methods
A more in-depth haplotype analysis was conducted using R haplo.score and haplo.glm
functions.176 Haplostats was shown to perform well compared to other methodologies, par-
ticularly for detecting common haplotype associations.175 This is relevant for miR-137 as
the common alleles in the MIR137HG are associated with risk in GWAS.
III.2.7.1 Global Analysis
Haplotype data included unphased genotypes for all GWAS SNPs (rs1625579, rs1198588,
rs2660304) and the VNTR. Global score tests of association use an additive GLM to regress
diagnosis on haplotype pairs for an individual from unphased genotype data. Haplotypes
were excluded with frequencies <0.8% for the combined diagnosis group, and <1% for AOS
and COS groups.
III.2.7.2 GLM Analysis
Haplo.glm was used to test magnitude and direction of individual haplotype effects
relative to a common reference haplotype using a Wald type test. Rare haplotypes (<0.9%)
were grouped and included in the model. Typically, the major haplotype is used as the
reference, however, in order to evaluate effect size of the common haplotype, we referenced
on the second most frequent haplotype per haplo.stats documentation. Using haplo.glm, we
obtained ORs and 95% CIs.
III.2.7.3 CpG Island Prediction
The VNTR has high GC% content. To evaluate how the VNTR would contribute to
GC% content within the surrounding MIR137HG region, we conducted CpG island (CGI)
prediction using EMBOSS Cpgplot.184 Default settings were used: window size = 100, min-
imum length of an island = 200 bases, minimum average observed/expected ratio of C plus
G to CpG = 0.6, minimum average percentage of G plus C = 50.
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III.2.7.4 VNTR Conservation
Ensembl (release 95) Comparative Genomics was used to evaluate the conservation of
the VNTR in the 75 eutherian mammals alignment set. The evaluated sequence included
GRCh38.p12 Chromosome 1: 98,046,166-98,046,254.
III.3 Results
III.3.1 VNTR Genotype vs Diagnosis
The VNTR was genotyped in all patients and controls to evaluate association with
diagnosis. VNTR lengths ranged from three to fourteen repeats Table III.3. VNTR length
frequencies, particularly for longer repeats, differ from other groups’ previous findings. We
found through extensive troubleshooting that extended VNTR lengths (>9) require a high
GC content PCR system in order to consistently amplify. We suspect that differences in
allele frequencies between studies are due to different amplification protocols.
VNTR genotype was not significantly associated with COS (χ2=2.525, df=2, p=0.283)
and bordered on significance for AOS (χ2=4.774, df=2, p=0.09) and the combined AOS/COS
group (χ2=5.140, df=2, p=0.08)(Table III.2).
When comparing the VNTR allele frequencies in patients vs. controls, it is notable that
the frequency of the major allele VNTR length three repeats (3R) was higher in patients
(patient n=681, 3R Frequency=0.72; control n=306, 3R Frequency=0.68); this finding is
accordant with GWAS results where the major allele is the risk allele for all three SNPs
(rs1625579, rs1198588, rs2660304).23,38,39,70 Results from previous cloning and sequencing
(Chapter II) are also consistent with these findings and provide a potential mechanism of
risk, whereby the major allele (3R) would lead to increased miR-137 expression via decreased
del-miR-137 expression.
III.3.2 SNP/VNTR Genotypes Grouped vs Diagnosis
The chi-square analysis including both GWAS SNPs and the VNTR vs COS was not
significant (p=0.46) while both the AOS and combined groups were significant at the 0.05
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Table III.3: VNTR Allele and Genotype Distribution
Controls(n=306)
Combined
AOS/COS (n=678) AOS(n=590) COS(n=88)
Allele n Freq.(%) n Freq.(%) n Freq.(%) n Freq.(%)
3 417 68.1 980 72.3 849 71.9 131 74.4
4 71 11.6 121 8.9 103 8.7 18 10.2
5 30 4.9 65 4.8 61 5.2 4 2.3
6 16 2.6 44 3.2 42 3.6 2 1.1
7 21 3.4 39 2.9 34 2.9 5 2.8
8 19 3.1 30 2.2 23 1.9 7 4.0
9 13 2.1 30 2.2 24 2.0 6 3.4
10 11 1.8 28 2.1 25 2.1 3 1.7
11 10 1.6 10 0.7 10 0.8 - -
12 1 0.2 7 0.5 7 0.6 - -
13 3 0.5 - - - - - -
14 - - 2 0.1 2 0.2 - -
Total 612 1356 1180 176
Genotype n Freq. n Freq. n Freq. n Freq.
3/3 143 46.7 346 51.0 297 50.3 49 55.7
3/>3 131 42.8 288 42.5 255 43.2 33 37.5
>3/>3 32 10.5 44 6.5 38 6.4 6 6.8
Genotype n Freq. n Freq. n Freq. n Freq.
3/3 143 46.7 346 51.0 297 50.3 49 55.7
3/4 50 16.3 91 13.4 78 13.2 13 14.8
3/5 19 6.2 45 6.6 44 7.5 1 1.1
3/6 8 2.6 31 4.6 30 5.1 1 1.1
3/7 19 6.2 30 4.4 26 4.4 4 4.5
3/8 11 3.6 24 3.5 18 3.1 6 6.8
3/9 8 2.6 25 3.7 20 3.4 5 5.7
3/10 10 3.3 24 3.5 21 3.6 3 3.4
3/11 4 1.3 9 1.3 9 1.5 - -
3/12 1 0.3 7 1.0 7 1.2 - -
3/13 1 0.3 - - - - - -
3/14 - - 2 0.3 2 0.3 - -
4/4 1 0.3 6 0.9 4 0.7 2 2.3
4/5 4 1.3 4 0.6 3 0.5 1 1.1
4/6 3 1.0 4 0.6 4 0.7 - -
4/7 - - 4 0.6 4 0.7 - -
4/8 3 1.0 3 0.4 3 0.5 - -
4/9 4 1.3 1 0.1 1 0.2 - -
4/10 - - 2 0.3 2 0.3 - -
4/11 4 1.3 - - - - - -
4/13 1 0.3 - - - - - -
5/5 2 0.7 2 0.3 2 0.3 - -
5/6 1 0.3 4 0.6 4 0.7 - -
5/7 - - 3 0.4 3 0.5 - -
5/8 1 0.3 3 0.4 2 0.3 1 1.1
5/9 - - 1 0.1 - - 1 1.1
5/10 - - 1 0.1 1 0.2 - -
5/13 1 0.3 - - - - - -
6/6 1 0.3 1 0.1 1 0.2 - -
6/7 1 0.3 1 0.1 - - 1 1.1
6/9 1 0.3 - - - - - -
6/10 - - 1 0.1 1 0.2 - -
6/11 - - 1 0.1 1 0.2 - -
7/9 - - 1 0.1 1 0.2 - -
7/11 1 0.3 - - - - - -
8/8 1 0.3 - - - - - -
8/10 1 0.3 - - - - - -
8/11 1 0.3 - - - - - -
9/9 - - 1 0.1 1 0.2 - -
- Dashes indicate variants not found in the diagnostic group
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level (p=0.031, OR = 0.65; p=0.031, OR = 0.66 respectively). Odd ratios of less than one
suggest that having one or more copies of the VNTR with >3R may be protective. This
preliminary result in conjunction with other VNTR results implicates the VNTR as a SZ
risk factor.
III.3.3 Haplotype Analyses
To assess genetic risk architecture for each diagnostic group haplotype analysis was
performed using SNP and VNTR data. Results are shown in Table III.4 and Figures III.2,
III.3, and III.4. The common haplotype (TT3T) frequency was 54.7% in controls, 57.3%
in combined, 57.5% in AOS and 56.5% in COS patients. The global haplotype analysis
was significant for all diagnosis groups (Combined global-stat=21.36, df=7, p=3.3e-03, AOS
global-stat=21.85, df=7, p=2.7e-03, COS global-stat=20.16, df=5, p=1.2e-03) indicating
overall association of the haplotype block with SZ. Haplotype risk scores indicate a significant
protective effect for the (TT>3T) group in the combined(p=0.014) and AOS (p=0.019)
groups. In the COS group, the directionality of the protective effect of the (TT>3T) was
consistent but failed to reach significance (p=0.096) likely due to the smaller sample size and
lack of power to detect a significant effect. Furthermore, significant haplotype associations
to risk were also seen for three rare haplotypes. The combined and AOS groups showed
significant association to the rare AT3G (Combined p=0.012; AOS p=0.007) and TG3T
(Combined p=0.005; AOS p=0.002) haplotypes. The COS groups also had a significant score
for the rare haplotype (AT3T p=1.0e-5). Together, these results confirm overall association
within the MIR137HG region and suggest combinatorial effects of the VNTR and the GWAS
SNPs leading to both protective and rare high risk haplotype associations in patients with
AOS and COS.
Results of the individual haplotype analysis allowed us to assess magnitude and direction
of effect for significant haplotypes (Table III.4). We used the protective haplotype (TT>3T)
as the reference to assess risk effects for the major haplotype. Results are consistent with
the global haplotype score results. For the combined diagnosis group, individual haplotype
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Table III.4: Individual Haplotype GLM Results

















TT3T 0.560 0.576 0.035 1.32(1.01-1.69) 0.578 0.034 1.34(1.02 - 1.75) 0.565 0.327
TT>3T 0.251 0.202 Ref. 1 0.202 Ref. 1 0.193 Ref. 1
Rare Group 0.024 RG 2.36(1.12-4.97) 0.013 RG 2.22(1.18-4.18) 0.524 RG
TT>3G 0.000 0.002 RG 0.001 RG 0.006 RG
TG3T 0.000 0.012 RG 0.014 RG 0.000 NA
TG3G 0.006 0.003 RG 0.003 RG 0.006 RG
TG>3T 0.002 0.006 RG 0.007 RG 0.000 RG
TG>3G 0.005 0.001 RG 0.000 RG 0.006 RG
AT3T 0.006 0.017 0.112 0.011 RG 0.052 0.0008 10.28(2.66-39.80)
AT3G 0.002 0.016 0.022 10.49(1.45-81.7) 0.018 0.016 11.81(1.57-88.61) 0.000 RG
AT>3T 0.007 0.001 RG 0.002 RG 0.005 RG
AT>3G 0.000 0.007 RG 0.007 RG 0.005 RG
AG3T 0.000 0.001 RG 0.001 RG 0.000 NA
AG3G 0.108 0.099 0.376 0.094 0.533 0.122 0.321
AG>3T 0.000 0.001 RG 0.001 RG 0.000 NA
AG>3G 0.053 0.058 0.282 0.061 0.18 0.041 0.717
Global Haplotype Score 0.003 0.00296 0.0012
*SNP order: rs1198588, rs2660304, VNTR, rs1625579)
NA - Haplotypes that were excluded from global analysis due to low frequency (<1%), or that were not found in patients or controls in the haplo.glm analysis
RG - Haplotypes grouped in the ”rare group” glm analysis
Ref. - the reference haplotype used for the glm analysis
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Figure III.2: Global haplotype statistic is significant indicating an overall pattern of asso-
ciation with this haplotype region. This is expected as there have been multiple GWAS
studies associating this region with diagnosis. The pattern of risk scores shows a potential
protective effect for the TT>3T haplotype, and a potential risk association with the AT3G
haplotype.
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Haplotype Risk Score Estimation for Adult Onset Diagnosis


































Figure III.3: Global haplotype score is significant for AOS group. Again, this is expected
as there have been previous GWAS findings linking this genomic region with disease. The
pattern of haplotype risk scores shows potential significant protective effects for the (TT>3T)
group and potential risk association for the rare haplotypes TG3T and AT3G.
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Figure III.4: Global haplotype score is significant for our childhood onset cohort. There is
a different haplotype risk score pattern with potential high risk associations with the AT3T
haplotype indicating a potential contribution to more severe phenotypes.
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analysis found significant effects for the common haplotype TT3T(OR: 1.32, p=0.035), as
well as for the rare haplotype AT3G(OR: 10.49, p=0.022), and the rare haplotype group(OR:
2.36, p=0.024). When the minimum frequency is lowered to 0.8% to allow for evaluation of
the TG3T haplotype, complete separation is seen in the model with the TG3T haplotype
only seen in cases and not in controls, and the rare haplotype group is no longer significant
(p=0.507). This complete separation confirms the global haplotype result that the TG3T
haplotype is a rare high risk haplotype and indicates that the TG3T haplotype is driving
the risk association with the rare haplotype group. An increased sample size will be needed
to better assess the TG3T haplotype within the individual GLM model. Similar results
were found for the AOS diagnosis group with significant risk associations for haplotypes
TT3T(OR: 1.34, p=0.034), AT3G(OR: 11.81, p=0.016), and the rare haplotype group(OR:
2.22, p=0.013). With the minimum haplotype frequency lowered to 0.9%, again we see
complete separation with the TG3T haplotype being only found in patients, and the rare
haplotype group becoming non-significant (p=0.219). The risk association of the common
TT3T haplotype relative to the TT>3T haplotype implicates the major VNTR 3R allele
as a driver of risk for the TT3T haplotype. Genotyping allowed us to conduct LD analysis
of the VNTR and GWAS SNPs within our control cohort. Results indicate low linkage
between the VNTR and GWAS SNPs (VNTR LD versus: rs1198588 D′= 0.03, r=0.02;
rs2660304 D′=0.04, r=0.03; rs1625579 D′=0.02, r=0.01) suggesting that VNTR instability
is not haplotype dependent, and that GWAS SNPs would not be tagging the VNTR. This
is consistent with previous VNTR LD findings and supports a role for other regional risk
variants.
It is apparent from our data that the VNTR is not the only risk variant within the region
as evidenced by low LD with the GWAS SNPs, the lack of risk association with the AG3G
haplotype and high risk associations found with the rare AT3G and TG3T haplotypes. The
high risk of these rare haplotypes suggest that recombination of the rs2660304 SNP region
may also be contributing to risk. In order to evaluate if recombination alone may contribute
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to risk independent of the VNTR, we conducted global and individual haplotype analyses
with only SNP genotypes, excluding the VNTR variant. Results of these analyses confirm
that recombination of the rs2660304 SNP alone is a driver of risk (Global haplotype scores:
Combined: TGT p=2.8e-3, ATG p=1.9e-3; AOS: TGT p=1.2e-3, ATG p=9.9e-3. Individual
GLM: Combined TGT OR: 12.24 p=0.015, ATG OR: 12.22 p=0.015; AOS TGT OR: 14.40
p=9.0e-3, ATG OR: 13.27 p=0.012). These results demonstrate that recombination of the
rs2660304 region contributes to risk independently of VNTR genotype, through an unknown
mechanism.
A different pattern of association was found for COS diagnosis. The rare haplotype
AT3T was significant (haplo.glm OR: 10.28, p=8.0e-4), and no association was found with
the common TT3T haplotype. This result is consistent with our previous data demonstrat-
ing a genotype association with the minor rs1198588 genotype (A/A) and COS diagnosis.
These results may be spurious due to sample differences or they may represent an etiological
difference between COS and AOS. Further functional studies will be needed to confirm risk
association.
As seen in Table III.4, confidence intervals for rare haplotype associations are large
due to low haplotype frequencies, larger sample sizes will be needed to determine more
accurate effect sizes. These results demonstrate a complex pattern of risk architecture for
theMIR137HG region with shorter VNTR lengths and recombination of the rs2660304 region
both independently contributing to risk for SZ diagnosis.
III.3.4 CpG Island Prediction
Two putative CGIs are located within the MIR137HG genome region(Figure III.5). One
smaller 247 base CGI spans HG19 chr1:98456956 – 98457203 and a larger 647 base CGI
spanning HG19 chr1:98457215 – 98457862. These regions overlap a large portion of pri-miR-
137 exon 3, including the VNTR, pre- and mature miR-137 sequences and span into intron
3. The VNTR would contribute to CGI length indicating potential associations epigenetic
regulation.
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EMBOSS Predicted CpG Islands
E3E2
Figure III.5: The borders of the two predicted CGIs are indicated with red arrow heads. The
location of the CGI spanning across exon 3 includes the high GC content VNTR sequence
and length of the VNTR would contribute to length of the overlapping CGI.
65
III.3.5 Human Specific VNTR Expansion
Previous research demonstrates a significant correlation between VNTR genotype and
cognitive phenotypes.127 We suspect that expansion of the VNTR is evolutionarily advan-
tageous for cognition, due to its potential negative regulation of miR-137. To evaluate the
VNTR in the context of mammalian evolution we used Ensembl Comparative Genomics to
evaluate conservation. Sequence alignment shows that the VNTR length of 2 repeats and the
surrounding region is highly conserved throughout the primate lineage (Figure III.6). How-
ever, the expansion of the VNTR to 3 repeats is human lineage specific indicating that longer
VNTR repeats may have contributed to increased human cognitive abilities and supports a
role for the VNTR in risk for SZ.185
III.4 Discussion
Through this work, we characterize risk architecture of the MIR137HG genome region
and describe novel genetic associations suggesting that shorter VNTR length contributes
to MIR137HG SZ risk. The GWAS variants (rs1198588, rs2660304, rs1625579) and the
VNTR element located upstream of the pre-miR-137 sequence were genotyped in patients
and controls, which allowed us to conduct a haplotype analysis on our AOS, COS, and
combined diagnosis groups, as well as evaluate individual variant associations in our COS
cohort. Importantly, we found novel associations with the common haplotype TT3T relative
to the TT>3T haplotype. This finding is consistent with previous GWAS results which
establish associations with the major SNP alleles (T,T,T). These results indicate a novel
significant protective effect for the TT>3T haplotype relative to the TT3T haplotype and
implicate the 3R VNTR as a driver of risk association for SZ.
We predict that increased VNTR repeats negatively regulate miR-137 expression result-
ing in subsequent increases in neurodevelopmental processes. The 3R haplotype association
with diagnosis is likely due to increased miR-137 expression mediated by the shorter 3R
allele in conjunction with a genetic background that already predisposes for repression of
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Comparative Genomic Conservation of the VNTR
homo_sapiens             Human          CCAAGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTACCGCTGCCGCTGCTACTGCCGCCGCCGCCGCCACCAGAACTCT  
pan_paniscus             Bonobo         CCAAGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCCGCCGCCACCAGAACTCT  
pan_troglodytes          Chimpanzee     CCAAGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCCGCCGCCACCAGAACTCT
gorilla_gorilla          Gorilla        CCAAGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCCGCCGCCACCAGAACTCT
pongo_abelii             Orangutan      CCAAGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCCGCCGCCACCAGAACTCT
nomascus_leucogenys      Gibbon         CCGAGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCCGCCGCCACCAGAACTCT
cercocebus_atys         Sooty Mangabey CCAAGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCTGCCGCCACCAGAACTCT
mandrillus_leucophaeus   Drill CCAAGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCTGCCGCCACCAGAACTCT
papio_anubis             Baboon         CCAAGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCTGCCGCCACCAGAACTCT
macaca_fascicularis      Macaque        CCAAGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCTGCCGCCACCAGAACTCT
macaca_mulatta           Macaque        CCAAGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCTGCCGCCACCAGAACTCT
macaca_nemestrina        Macaque        CCAAGCTG-CGCTGCCGCTGCTACCGCTGCCGCTGCTAC--------------CTGCCGCCGCTGCCGCCACCAGAACTCT
chlorocebus_sabaeus      Vervet         CCAAGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCCGCCGCCACCAGAACTCT
colobus_angolensis_palliatus  Colobus CCAAGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCCGCCGCCACCAGAACTCT
rhinopithecus_bieti Snub-nosed CCAAGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCCGCCGCCACCAGAACTCT
rhinopithecus_roxellana CCAAGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCCGCCGCCACCAGAACTCT
aotus_nancymaae Ma’s night     CCAGGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCCGCCGCCACCAGAACTCT
cebus_capucinus Capuchin       CCAGGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCCGCCGCCACCAGAACTCT
saimiri_boliviensis Squirrel Monkey CCAGGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCTAC---------------TGCCGCCGCCGCCGCCACCAGAACTCT
carlito_syrichta Tarsier        CCACGCTGCCGCCGCTGC------------------------------------------CGCCGCCGCCACCGGGACTCC 
otolemur_garnettii Bushbaby       CCAAGCTGCCGCTGCCGCTGCTACCGCTGCCGCTGCT---GCTGCCG-------T-----------CGCCTCCAGAACTCT 
Figure III.6: Sequence alignment of the VNTR across the primate lineage shows high conservation of the region and the
expansion from 2 repeats to 3 repeats in the human line. This human lineage specific VNTR expansion may contribute to
associations with this region and intelligence as well as associations with SZ and ASD.
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neurodevelopmental pathways. The 3R allele is a human lineage specific expansion indicat-
ing that longer VNTR repeats may have contributed to increased human cognitive capacity
and potentially play a role in the etiology of both SZ and ASD.185 This cognitive trade-off
model is extensively reviewed in Sikela and Searles Quick (2018) and supported by findings
from the Sikela lab, where they describe a similar pattern with the Olduvai protein do-
main family (formerly known as DUF1220).185 Genetic findings support the gain-of-function
and cognitive trade-off models with minor alleles in the MIR137HG locus having genome
wide significant associations with ASD. Additional GWAS associations have been found in
the region for intelligence, cognitive performance and function, and educational attainment,
supporting a role for miR-137 in the evolution of increased human cognition.186–190
The human lineage specific expansion of the VNTR supports a potential role for this
variant in the evolution of increased cognitive abilities in humans.185 Longer VNTR repeats
would result in a competitive cognitive advantage associated with suppression of miR-137
expression. This is supported by GWAS associations with intelligence and cognitive perfor-
mance within the MIR137HG locus.186,187,189,190 Additionally, VNTR length may contribute
to risk for other neurodevelopmental disorders. While SZ and ASD share a subset of phe-
notypes and risk variants, there are several known pathological variants and pathways in
which the direction of risk for SZ is the opposite of risk direction for ASD, also known as
the diametric hypothesis.159,160 The MIR137HG locus follows this diametric pattern of as-
sociation. Findings from GWAS have identified minor allele SNPs within the MIR137HG
locus to be associated with ASD, which is the opposite finding for GWAS SZ SNPs which
are all major alleles.161 Conditional knockout of miR-137 in mice lead to social deficits and
unusual repetitive behavior, phenotypes that are associated with ASD.136 Individuals with
microdeletion of MIR137HG had a syndrome presenting with intellectual disability, ASD,
and obesity.20,78,162–164 We predict that longer VNTR lengths may confer risk for ASD as
miR-137 loss-of-function results in ASD like phenotypes. These findings support an evolu-
tionary role for VNTR expansion in the development of the human brain.
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Additional significant novel associations involving the minor SNP rs1198588 “A” allele
were found in both haplotype and independent genotype associations. Haplotype AT3G
was significant in the AOS diagnosis group and haplotype AT3T was significant in the COS
diagnosis group. The novel finding of a significant association between rs1198588 “A/A”
genotype and COS diagnosis is an important result of this study and is consistent with the
rare haplotype associations. We suspect that an increase in miR-137 expression caused by
the “A” allele contributes to a gain-of-function pathology when combined with the 3R VNTR
potentially contributing to the more severe COS phenotype.
We suspect that the 3R VNTR and the rs1198588 “A” allele both contribute to risk
in the region but are not the only pathogenic variants, as we found no association with
the common AG3G haplotype. This prediction is supported by the finding of another rare
haplotype TG3T with the greatest risk association (OR: 1.54e14). These findings suggest
that other elements within the genomic region may be etiologically relevant.
Interestingly, rare high risk haplotypes with recombination of the rs2660304 region were
identified. Specific underlying risk mechanisms are unknown, however we predict that cis-
acting repressive elements for both the major (TTT) and minor (AGG) haplotypes would
be disrupted by recombination. This would result in increased miR-137 expression for the
recombined (TGT and ATG) haplotypes, which would contribute to gain-of-function risk for
SZ. Further functional analyses will be needed to validate these high risk associations and
determine causal mechanisms.
The specific functional variant underlying association with the TG3T is not known,
however, we suspect that there are cis elements within the rs2660304/rs1625579 haploblock
that work together to repress miR-137 expression and when the haplotype is recombined
as in the AT3G and the TG3T haplotypes the process of tandem cooperative repression
is disrupted and there is an increase in miR-137 expression, contributing to the gain-of-
function pathology. Larger sample sizes and functional analyses will be needed to confirm
rare haplotype associations and to determine the true causal variants. These findings support
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an epistatic risk variant model with the rs1198588 minor “A” allele, the VNTR 3R, and
other unknown cis-acting elements contributing to SZ risk through aberrant miR-137 gain-of




EVALUATING POTENTIAL DOWNSTREAM IMPACTS OF
ALTERNATIVE MIR-137 PROCESSING PATHWAYS
IV.1 Introduction
We previously characterized novel transcripts with the mature miR-137 sequence spliced
out termed del-miR-137. These alternatively spliced transcripts appear to be modulated by
the nearby VNTR length and through independent epigenetic mechanisms associated with
development. However the molecular mechanisms underlying the association with VNTR
length and other potential epigenetic regulators are unknown. Here we evaluate potential
molecular mechanisms for VNTR risk associations as well as other potential epigenetic reg-
ulatory pathways. We use in silico analyses to visualize expression of both pri-miR-137
and pre-miR-137 transcripts in the brain across development. Additionally, we evaluate ex-
pression of potential miR-137 regulatory proteins across development and how expression
patterns may contribute to the regulation of miR-137 transcripts. Finally, we conduct gene
pathway analysis to examine potential non-canonical lncRNA functions of the MIR137HG
transcripts and how they may impact neurodevelopment and contribute to pathology.
We showed that high GC% content of the VNTR would contribute to the length of an
overlapping CGI. We hypothesize that the high GC% content of the region may contribute
to regulation of alternative pri-miR-137 splicing. Several epigenetic regulatory elements
associate with DNA containing high GC% content including DNA methylation and MECP2.
MECP2 localization is more accurately predicted by GC% than CpG% and localizes to
regions with high GC% content.121 MECP2 can directly alter alternative splicing through
recruitment of splicing factors.191 Because the VNTR is increasing the GC% of the region
we predict that the VNTR may contribute to alternative splicing through localization of
MECP2. In addition, MECP2 inhibits pre-miR-137 processing by recruiting factors that
bind to the apical loop structure, and is a competitive inhibitor of microprocessing through
binding to DGCR8.192,193 To evaluate these hypotheses we examined expression of miR-137,
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MECP2 and DGCR8 across human brain development. We also investigated the relationship
between the pri- and pre-miR-137 transcripts, which maybe an indicator of the alternative
splicing observed in Chapter II.
Using in silico analyses, we further characterize the regulatory impacts of alternative
splicing. The pri-miR-137 is capped and tailed and has the potential to be exported out
of the nucleus. We predict that the del-miR-137 transcripts are also capped and tailed as
we utilized OligoDT methods to conduct cDNA synthesis as part of cloning and sequencing
(Chapter II). This lead us to question possible alternative functionality of the pri-miR-137
and del-miR-137 transcripts within the cytoplasm. Long non-coding RNAs are known to
have regulatory function in RNA pathways and we predict that the del-miR-137 lncRNA
may have regulatory function and possibly contribute to neurodevelopmental regulation.
One lesser known function of lncRNAs is their ability to regulate miR networks by acting
as competitive endogenous RNAs (ceRNAs).194–196 CeRNAs are lncRNAs that contain seed
sequence binding sites for miRs and regulate RNA networks in the cytoplasm through seques-
tration of other mature miRs. Competitive binding to the lncRNA would prevent the various
miRs from inhibiting their corresponding downstream pathways and may provide additional
regulatory function for the pri-miR-137 and del-miR-137 sequence, once it is exported out of
the nucleus. In order to evaluate potential ceRNA processing ability of pri-miR-137 and del-
miR-137 transcripts, we conducted seed sequence binding site prediction for different miRs
within the pri-miR-137 RNA sequence. To evaluate potential impacts of the competitive
miR sequestration on corresponding downstream pathways, we then conducted target gene
prediction for the various potentially sequestered miRs followed by gene network analysis.
Alternative processing of the pre-miR-137 sequence may also impact regulation of down-
stream RNA networks. Through structural analysis of the pre-miR-137 we also describe a
potential novel isomiR within the pre-miR-137 sequence. The function of the nuclear mi-
croprocessor is complex and relies on multiple cis-acting pri-miR sequence elements. The
relative importance of each sequence element was evaluated in seminal work by Kwon et.
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al.112 They demonstrated that the mGHG element determines the DROSHA cleavage site
with single-nucleotide resolution. We describe duplicate GHG and CNNC elements that the
DROSHA complex may utilize to cleave the pre-miR-137. The product of this alternative
DROSHA cleavage would generate a slightly longer stem loop. This is relevant because
stem-loop length is utilized in the cytoplasmic processing by Dicer.197 The seed sequence
of miR-137 is generated in the cytoplasm by the Dicer complex, which is known to have
less precise processing precision than the nuclear microprocessor complex, and can shift
the pre-miR-137 cleavage site in a process known as alternative dicing.198 We use in sil-
ico pathway analyses to evaluate potential isomiR functionality and contribution to risk in
neurodevelopmental disease.
IV.2 Methods and Materials
IV.2.1 In-silico Analyses
IV.2.1.1 Visualizing Relevant RNA Sequencing Data
Data from BrainSpan Atlas of the Developing Human Brain was used to evaluate expres-
sion of the pri-miR-137 and pre-miR-137 across development.199 Transcript reads (RPKM)
were averaged for all pri-miR-137 exons and graphed together with the pre-miR-137 reads.
This allowed us to visualize expression patterns of both transcripts over time. We were also
able to map expression patterns between different brain regions.
General expression patterns for the predicted regulators of pre-miR-137 DGCR8 and
MECP2 from the Brainspan data were evaluated using the Expression pattern functionality
on the Schizophrenia Database website (www.szdb.org). For the PFC-MFC group which
includes the brain regions: Primary motor cortex, Primary somatosensory cortex, Ventrolat-




The miRDB website was used to generate a list of predicted miRs that bind to the del-
miR-137 transcripts.200 This list was then input into the miRSystem database to determine
potential target genes and conduct pathway ranking analysis.201
IV.2.1.3 isomiR
We used MirGeneDB2.0 to visualize RNA sequencing data for miR-137, which showed
shorter mature miR reads which may be potential isomiRs.202 This lead us to evaluate poten-
tial alternative Dicer processing sites and the resulting functionality of potential alternative
seed sequences generated. Using TargetScanHuman Custom Release 5.2 we generated a list
of potential target genes for three new putative seed sequences (AUUGCUU, UUGCUUA,
UGCUUAA).203 We input the putative target genes through pathway analysis using PAN-
THER version 14.0 to assess affects on potential down-stream gene pathways.
IV.3 Results
IV.3.1 In-silico Analyses
IV.3.1.1 Transcript Expression Across Development
Analysis of the BrainSpan RNA sequencing data, showed a pattern of low pri- and pre-
miR-137 expression in early embryonic development, followed by increased miR-137 expres-
sion in the developing fetal brain, which declines around the time of birth (Figure IV.1). This
is consistent with miR-137 functionality as a regulator of neurodevelopment. Precise regula-
tion of expression is necessary for normative neurodevelopment, therefore multiple modalities
of regulation will need to work in tandem. Alternative splicing of the pri-miR-137 and ex-
pression of del-miR-137 provides a novel regulatory mechanism. Comparing expression of
the pri-miR-137 transcripts to the pre-miR-137 in the BrainSpan data will allow us to de-
termine if alternative splicing is occurring. There are developmental time periods where the
directionality of the pri-miR-137 and the pre-miR-137 expression differ. These time periods,
which are highlighted in green, indicate that overall transcription of the MIR137HG region
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Pri-miR-137 Expression DGCR8 Expression MECP2 Expression Pre-miR
Figure IV.1: RNA sequencing data from BrainSpan was graphed for average RPKM across all brain regions for each devel-
opmental time point. BrainSpan data shows low expression for pri- and pre-miR-137 transcripts in the embryonic stage, and
increased expression for both transcripts during the prenatal period of development, with a decrease in expression postnatally.
Intriguingly, there are time points highlighted in green where the overall pri-miR transcript is increasing in expression while
the pre-miR either stays consistent or decreases. These opposite expression patterns may be mediated by alternative splicing,
and potential expression of the previously described del-miR transcripts. Expression patterns for DGCR8 and MeCP2 are also
depicted. The directionality of the pre-miR-137 transcripts is opposite of MeCP2. Whereas the directionality of pre-miR-137
expression is consistent DGCR8. These expression patterns are consistent with MECP2 down-regulation of pre-miR-137 and
DGCR8 up-regulation of pre-miR-137.75
is increased while pre-miR-137 expression is decreasing. This pattern of expression may be
mediated by alternative splicing and the expression of the del-miR-137 transcripts.
To evaluate how the regulators MECP2 and DGCR8 may contribute to changes in
MIR137HG expression we also used BrainSpan data to map their expression across de-
velopment. Results show that during early development expression of DGCR8 and miR-137
is low, while expression of MECP2 is high. This indicates that MECP2 expression may
down-regulate miR-137 expression during this time period. Intriguingly, there are time peri-
ods highlighted in green when the direction of the pri-miR-137 is increasing while expression
of pre-miR-137 is decreasing or remaining consistent. During these time periods of incon-
sistent pri-miR-137 and pre-miR-137, pri-miR-137 there is an increase in MECP2(Figure
IV.1) and a decrease in DGCR8. While speculative, these patterns of expression support
down-regulation of pre-miR-137 via MECP2 and up-regulation of pre-miR-137 via DGCR8.
These findings are consistent with previous research indicating that processing efficiency
by DGCR8/DROSHA is a better predictor of mature miR expression115 and that MECP2
expression can act as a microRNA repressor.204,205 We postulate that VNTR length would
contribute to down-regulation of pre-miR-137 through increased localization of MECP2 to
exon 3 mediated by the high GC% of the VNTR sequence. Paradoxically, this would con-
tribute to the upregulation of the pri-miR-137 exons through splicing and expression of
the del-miR-137 transcript, which is also consistent with expression patterns (Figure IV.1).
This mechanism may underly haplotype associations mediated by the VNTR and the VNTR
length associations with alternative splicing.
IV.3.1.2 ceRNA Pathway
To assess potential additional functionality of the full length unprocessed pri-miR-137
and spliced del-miR-137 transcripts, we evaluated the potential binding of additional miRs
using miRDB. We found predicted binding sites for 54 miRs. Using miRSystem, a list of
over 2,653 potential target genes was generated from the predicted binding miRs. Pathway
analysis of these genes found ‘Axon guidance’ as the top ontological term associated with
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this gene list. Axon guidance pathway genes are known to be associated with risk for
schizophrenia.206 These results indicate that del-miR-137 and unprocessed exported pri-
miR-137 may up-regulate axon guidance pathways through sequestration of associated miRs.
IV.3.1.3 isomiR
Alternate GHG and CNNC sequence elements were found within the pre-miR-137 se-
quence (Figure IV.2). To evaluate potential functionality of the putative isomiRs we used
TargetScanHuman Custom Release 5.2 to generate a list of potential target genes for the
new seed sequences(AUUGCUU, UUGCUUA, UGCUUAA).203 Results found 636 conserved
target genes with 695 conserved sites for AUUGCUU. Pathway enrichment analysis showed
‘vesicle-mediated transport in synapse’ as the top enriched biological process. The seed
sequence prediction for UUGCUUA found 386 conserved target genes, with a total of 420
conserved sites. Pathway enrichment analysis showed no significantly enriched terms. Target
gene prediction for UGCUUAA found 297 conserved target genes with a total of 307 con-
served binding sites. Results of pathway enrichment found the term ‘positive regulation of
transcription, DNA-templated’ as the top biological process. Several positive transcription
regulation terms were found for the AUUGCUU seed as well. These results show that there
may be functional alternative processing of the pre-miR-137. Expression of these isomiRs
would result in down regulation of the associated biological processes including vesicle trans-
port, synaptic signaling and positive regulation of transcription.
IV.4 Discussion
Analysis of Brain Span RNA sequencing data shows that relative overall expression of
miR-137 is high in fetal development and then declines postnatally. This expression pat-
tern is consistent with miR-137 as a critical regulator of neurodevelopment. Interestingly,
our data analysis show there were times during development where overall expression of the
pri-miR-137 increased but the expression of miR-137 decreased. We predict that alternative
splicing of the region through epigenetic regulation may contribute to these diametric expres-
sion patterns. Up-regulation of alternative splicing during the fetal time period is consistent
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Pre-miR Sequence Motifs and RNA Sequencing Data Indicate Potential isomiRs
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Figure IV.2: Potential novel DROSHA binding sites within the pre-miR sequences are highlighted in orange. Alternative binding
by Drosha may cleave the pre-miR-137 with extended length and potential to shift the seed sequence generation by Dicer. RNA
seq results are consistent with this hypothesis with a decrease in reads for the first few seed sequence bases. This indicates that
there may be a second isomiR generated from the same pre-miR-137 stem loop.
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with our previously described cloning and sequencing results where we found significantly
increased splicing of transcripts containing the 3R VNTR allele in the fetal time point. This
differential regulation would have to be mediated through an epigenetic mechanism since
VNTR genotype was consistent between groups. We hypothesize that epigenetic regulation
of the region is mediated via MECP2. The high GC% content of the VNTR would be suf-
ficient for MECP2 localization. We predict that this pattern of MECP2 localization would
increase alternative splicing, as it is known to be a positive regulator of splicing through
splice factor recruitment. Brain Span expression patterns support this prediction with in-
creased MECP2 expression during early embryonic development when miR-137 expression
is low, followed by a decline in MECP2 expression accompanied by increased miR-137 ex-
pression during early fetal development. Other relevant regulatory functions of MECP2 that
may contribute to repression of the miR-137 during early fetal development are recruitment
of factors that bind to the pre-miRapical loop and prevent binding by DGCR8, and compet-
itive binding of MECP2 binding to the DGCR8 RNA binding sites. These results support
the putative mechanism of the VNTR’s contribution to alternative splicing through local-
ization of MECP2. Through this mechanism shorter length VNTR’s would contribute to
SZ pathology through reduced MECP2 localization and resulting decreases in alternative
splicing as well as the other microprocessing inhibitory functions for MECP2. It has been
shown that miR-137 is typically inefficiently processed indicating that normal miR-137 ex-
pression is low. Therefore, factors that lead to an increase in miR-137 processing such as
shorter VNTR lengths, decreased splice factor binding and splicing, and increased DGCR8
expression would all contribute the aberrant gain-of-function in SZ.
We found evidence for additional regulatory function of the del-miR-137 transcripts
through the ceRNA pathway. Predicted miR sites within the del-miR-137 transcript would
sequester miRs and would increase their downstream biological pathways. In the case of the
del-miR-137 transcript axon guidance is the top pathway associated which is consistent with
early fetal development when there is a decrease in miR-137 and up-regulation of neuronal
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migration. Pathway analysis of potential isomiR sequences also showed potential regula-
tion of relevant pathways including vesicle trafficking and regulation of transcription. This
complex pattern of regulation highlights the essential role that miR-137 plays in neurodevel-
opment where subtle changes in expression can have amplified consequences and therefore a




V.1 Foundations of MIR137HG Risk for Schizophrenia
Through this work we describe novel common and rare haplotype associations with the
MIR137HG gene and SZ, including the nearby VNTR element. These associations reveal
multiple epistatic risk variants and overall complex risk architecture for the region, that
may underly the common GWAS associations. Through transcript characterization at early
and late developmental time points we found novel del-miR-137 that would down regulate
mature miR-137 expression through alternative 5′ splicing within the pre-miR-137 sequence
in exon 3. Importantly, we found significant association with del-miR-137 transcripts and
the VNTR, where increased VNTR length transcripts had a higher frequency of the del-
miR-137alternative splicing. We present a novel regulatory mechanism for miR-137 through
increased regional GC% content and localization of the miR biogenesis regulator MECP2.
Additionally, we describe putative novel ceRNA function for the unprocessed pri-miR-137
and del-miR-137 transcripts. Through sequence structure analysis we describe a potential
isomiR of miR-137 overlapping the canonical sequence. Lastly, we detail genetic variants in
the context of human evolution and overall associations with complex disease.
V.1.1 Elucidating MIR137HG Genetic Risk Architecture
Haplotype analysis allowed us to detect both rare and common risk variants within the
MIR137HG region and to evaluate the VNTR within the context of the corresponding re-
gion of LD. Results indicate a significant protective effect for longer length VNTR repeats.
Additionally, we describe novel rare high risk haplotypes containing the rs1198588 “A” allele
and with haplotypes that have been recombined between the rs2660304 and rs1625579 SNPs.
Figure V.1 outlines the findings from our haplotype analysis. These results show three sepa-
rate epistatic risk variants in the region. The risk variants are all predicted to contribute to
the pathological miR-137 gain-of-function phenotype found in patients. Further studies will
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Haplotype Risk Variants in Relation to Gene Location
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Figure V.1: The pri-miR-137 exons are shown across this top in blue and the locations of
the haplotype SNPs and VNTR is shown relative to pri-miR exons. Significant haplotypes
are shown below with the protective haplotype highlighted in green and the risk associated
haplotypes highlighted in red. Haplotype frequency and scores are shown to the right of
each transcript and transcripts are listed in order of ascending risk score. Potential risk
variants and their effect on miR-137 expression is shown across the bottom of the graph. The
rs1198588 minor “A” allele appears to contribute to risk in the context of rare haplotypes.
The 3R is also a predicted risk variant and we predict that this is mediated by GC content
of the sequence. Interestingly, recombined haplotypes (i.e. haplotypes that have opposite
major and minor alleles at the rs1625579 and rs2660304 SNPs also appear to contribute
to rare high risk haplotypes. We predict that this may be due to cis acting elements on
opposite sides of the region that work to repress miR-137 expression. When the haplotype
is recombined these elements can no longer repress miR and it would greatly increase risk
for diagnosis.
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be needed to confirm our findings and to validate functionality of these variants. These re-
sults mirror the complexity found in the risk architecture for SZ and contribute substantially
to our understanding of risk within the MIR137HG region.
V.1.2 Potential Molecular Mechanisms Contributing to Risk
Within the brain, miR-137 is a developmental network hub requiring precise expression
to properly regulate down stream target gene pathways.79 Expression of miRs is largely
dependent on processing efficiency, which itself is regulated at multiple levels.193 miR-137
has been shown to have a number of different patterns of regulation including co- and post-
transcriptional processing by the DROSHA/DGCR8 complex.108 Co-transcriptional pro-
cessing is more efficient than post-transcriptional processing. A study of miR processing
found low processing efficiency for miR-137, indicating that co-transcriptional processing
of miR-137 is infrequent.108 Our results from cloning and sequencing of pri-miR-137 tran-
scripts in human brain at both fetal and adult time points, provide several insights into the
regulatory mechanisms of miR-137. Through this work we discovered novel splice variants
of the miR-137 transcript termed del-miR-137. Expression of these del-miR-137 transcripts
is predicted to reduce processing efficiency of miR through a potential mirtron pathway or
ablate processing all together resulting in decreased miR-137 expression. Additionally, we
found associations between alternative splicing and VNTR length, and predict association
between shorter VNTR lengths and increased pre-miR-137 processing and expression, and
longer VNTR length associations to decreased pre-miR-137 processing and expression. We
predict that MECP2 localization mediates these associations due to the high GC% content
of the VNTR through multiple mechanisms.121 MECP2 is known to recruit splice factors,
miR repressor factors, and to competitively inhibit DGCR8 binding to miRs. All of these
functions would contribute to a decrease in pre-miR-137 processing efficiency, and would ex-
plain the associations with the VNTR and alternative splicing. We postulate a model where
shorter VNTR lengths would increase risk for SZ through decreased MECP2 localization and
increased pre-miR-137 processing, which would ultimately lead to increased miR-137 expres-
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Figure V.2: (a) In the high risk model, we predict that shorter VNTR lengths (blue arrows) would contribute to decreased
MeCP2 localization, which would increase processing efficiency and expression of miR-137 leading to contributing to over-
expression of miR-137 in patients during neurodevelopment. Additionally, Microprocessing would prevent ceRNA activity by
terminating transcription or cleaving the pri-miR-137 transcript. (b) In the low risk model, increased VNTR repeats >3 would
confer a protective benefit through increased GC% content and meCP2 localization. MeCP2 is known to down-regulate miRNA
biogenesis through competitive binding to DGCR8 and recruitment of negative regulators. MeCP2 may up-regulate del-miR-137
expression through splice factor recruitment, which may underly the positive association between VNTR length and del-miR-
137 splicing. While miR-137 may still be processed through the mirtron pathway, this pathway is far less efficient and would
decrease miR expression. Additionally, cytoplasmic ceRNA function of the del-miR-137 transcripts would contribute to the
upregulation of protective pathways. This figure was adapted from figures in: de Giorgio et al. 2013, Wong et al. 2017, and
Treiber et al. 2018.
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sion. In accordance with this hypothesis, increased expression of the microprocessor subunit
DGCR8 has been found in patients with SZ, which would also serve to increase pre-miR-137
processing efficiency.117 Our findings also indicate that transcript splicing is increased in the
fetal brain. In chapter II we describe a potential mechanism through mirtron processing in
which the excised del-miR-137 sequence could lead to a functional mature miR-137, however
this pathway is more inefficient than canonical processing and would still serve to reduce
overall miR-137 expression. All of these findings converge on pathogenic effects of increased
pre-miR-137 processing in SZ patients. This gain-of-function would be amplified at the early
neurodevelopmental stage when epigenetic downregulation of miR-137 appears to be criti-
cal. This would contribute to pathogenic neurodevelopment with expected overexpression
phenotypes consistent with SZ phenotypes and with the neurodevelopmental hypothesis for
SZ. Figure V.2 depicts the high and low risk models associated with differential processing
efficiency. Results from our in silico analyses demonstrate additional potential regulatory
pathways both for miR-137 expression and for regulation of down-stream pathways. We
found evidence for additional regulatory function of the del-miR-137 transcripts through the
ceRNA pathway. Predicted miR sites within the del-miR-137 transcript would sequester
other miRs and would increase their corresponding downstream biological pathways. In the
case of the del-miR-137 transcript, axon guidance is the top pathway associated which is con-
sistent with early fetal development when there is a decrease in miR-137 and up-regulation
of neuronal migration. Pathway analysis of potential isomiR sequences also showed potential
regulation of relevant pathways including vesicle trafficking and regulation of transcription.
V.2 The Contribution of altered MIR137HG Regulation to Complex Disease
This multitude of putative functional pathways for MIR137HG reflects its deep evolu-
tionary history. These alternative regulatory mechanisms for the mature miR-137 would
allow for decrease in expression without a total ablation of miR functionality, which under-
scores the critical role that miR-137 plays in regulating neurodevelopment and the precise
regulatory balance required to carry out proper brain development. This regulatory balance
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would be altered by selective pressure on the region for a decrease in miR-137 expression.
The human lineage specific expansion of the VNTR supports a role for this variant in the
evolution of increased cognitive abilities in humans.185 Longer VNTR repeats would re-
sult in a competitive cognitive advantage associated with suppression of miR-137 expression.
This is supported by GWAS associations with intelligence and cognitive performance within
the MIR137HG locus.186,187,189,190 Broad selection pressure for the upregulation of these
neurodevelopmental pathways would generate many different variants with small effect sizes
each contributing to minor increases in cognition while avoiding disruption of the delicate
balance required for proper neurodevelopment. Accumulation of these variants with small
effect sizes that are individually advantageous may result in pathogenic phenotypes such as
SZ and ASD. Associations with the commonMIR137HG haplotype and SZ diagnosis demon-
strates the role that genetic risk background plays in pathoetiology, as the common VNTR
allele would only confer risk on the background of other variants associated with increased
inhibition of neurodevelopmental pathways. We propose a model for the risk architecture for
the MIR137HG locus where selection acts on the region in close proximity to the miR-137
to enrich for high GC content and cis acting repressors. However as the repression of the
region begins to cross a threshold where repression becomes detrimental this may result in
ASD like phenotypes. In response to shifting inhibitory regulators, alternative variants that
confer up-regulation of the miR would be selected for. Positive regulators may be combined
or disrupted and in combination with other risk variants would contribute to SZ phenotypes.
Analysis of the 100 vertebrate track on UCSC shows that negative regulatory elements first
in the form of GC content and then the putatively functional rs1198588 “A” allele were
selected for in the primate lineage. It appears that after the VNTR repeat expanded pos-
itive regulatory elements were rapidly selected for (Figure V.3). The decreased frequency
of the ancestral allele for the proximal miR-137 SNPs rs2660304, rs1625579 may reflect this
pattern as the major allele at both SNPs is a “T”. This is also supported by our haplotype
analysis results showing epistatic protective effects for non-ancestral variants. In totality,
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Figure V.3: Mutation of each haplotype snp and the resulting haplotype are shown across
extant taxa. This allows us to visualize how the haplotype has changed throughout evo-
lutionary history. A pattern of selection for high GC content in the region appears to be
reflected in the haplotype changes. The rs1625579 “A” allele appears in the primate lineage
possibly reflecting a competitive advantage at this site. With the expansion of the VNTR
and putative down regulation of miR this may have decreased miR-137 function to detri-
mental levels, and may have driven a decrease in surrounding repressor functionality. This
can be seen as the ancestral allele for the proximal miR-137 SNPs rs2660304, rs1625579 are
currently the minor alleles and the current major allele at both SNPs is a “T”.
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our findings highlight the complex neurodevelopmental regulation of miR-137 and its role
in SZ etiology. This work contributes to our understanding of molecular mechanisms under-
lying the diagnostic associations with common MIR137HG genetic variants, and reveals a
dynamic evolutionary history that contributed to the development of the human brain.
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hika Kandaswamy, Matthew C Keller, James L Kennedy, Elaine Kenny, Lindsey Kent,
Yunjung Kim, George K Kirov, Sabine M Klauck, Lambertus Klei, James A Knowles,
Martin A Kohli, Daniel L Koller, Bettina Konte, Ania Korszun, Lydia Krabbendam,
Robert Krasucki, Jonna Kuntsi, Phoenix Kwan, Mikael Landén, Niklas L̊angström,
Mark Lathrop, Jacob Lawrence, William B Lawson, Marion Leboyer, David H Led-
better, Phil H Lee, Todd Lencz, Klaus-Peter Lesch, Douglas F Levinson, Cathryn M
Lewis, Jun Li, Paul Lichtenstein, Jeffrey A Lieberman, Dan-Yu Lin, Don H Linszen,
Chunyu Liu, Falk W Lohoff, Sandra K Loo, Catherine Lord, Jennifer K Lowe, Su-
sanne Lucae, Donald J MacIntyre, Pamela A F Madden, Elena Maestrini, Patrik K E
Magnusson, Pamela B Mahon, Wolfgang Maier, Anil K Malhotra, Shrikant M Mane,
Christa L Martin, Nicholas G Martin, Manuel Mattheisen, Keith Matthews, Morten
Mattingsdal, Steven A McCarroll, Kevin A McGhee, James J McGough, Patrick J
McGrath, and et al. Genetic relationship between five psychiatric disorders estimated
from genome-wide snps. Nature Genetics, 45:984 EP –, 08 2013. 91
[23] S. Ripke, A.R. Sanders, K.S. Kendler, D.F. Levinson, P. Sklar, P.A. Holmans, D.Y.
Lin, J. Duan, R.A. Ophoff, O.A. Andreassen, et al. Genome-wide association study
identifies five new schizophrenia loci. Nature genetics, 43(10):969–976, 2011.
[24] Steven C. Marcus and Mark Olfson. Outpatient antipsychotic treatment and inpatient
costs of schizophrenia. Schizophrenia Bulletin, 34(1):173–180, 2008.
[25] Andrew Moskowitz and Gerhard Heim. Eugen bleuler’s dementia praecox or the group
of schizophrenias (1911): a centenary appreciation and reconsideration. Schizophr Bull,
37(3):471–479, May 2011.
[26] Jeste DV Mueser KT. Clinical Handbook of Schizophrenia. Number ISBN 978-1-60623-
045-9. Guilford Press, New York, NY, USA, 2011.
[27] Michael J Owen, Akira Sawa, and Preben B Mortensen. Schizophrenia. The Lancet,
388(10039):86 – 97, 2016.
[28] Thomas H. McGlashan. Early Detection and Intervention in Schizophrenia: Research.
Schizophrenia Bulletin, 22(2):327–345, 01 1996.
[29] D R Weinberger. Implications of normal brain development for the pathogenesis of
schizophrenia. Arch Gen Psychiatry, 44(7):660–669, Jul 1987.
[30] R M Murray and S W Lewis. Is schizophrenia a neurodevelopmental disorder? Br
Med J (Clin Res Ed), 295(6600):681–682, Sep 1987.
[31] Floyd E. Bloom. Advancing a Neurodevelopmental Origin for Schizophrenia. Archives
of General Psychiatry, 50(3):224–227, 03 1993.
[32] David A Lewis and Jeffrey A Lieberman. Catching up on schizophrenia: Natural
history and neurobiology. Neuron, 28(2):325 – 334, 2000.
[33] Jeffrey A. Lieberman, Diana Perkins, Aysenil Belger, Miranda Chakos, Fred Jarskog,
Kalina Boteva, and John Gilmore. The early stages of schizophrenia: speculations
on pathogenesis, pathophysiology, and therapeutic approaches. Biological Psychiatry,
50(11):884 – 897, 2001.
[34] Sarah E Bergen and Tracey L Petryshen. Genome-wide association studies of
schizophrenia: does bigger lead to better results? Current opinion in psychiatry,
25(2):76–82, Mar 2012.
[35] Shaun M Purcell, Naomi R Wray, Jennifer L Stone, Peter M Visscher, Michael C
O’Donovan, Patrick F Sullivan, and Pamela Sklar. Common polygenic variation con-
tributes to risk of schizophrenia and bipolar disorder. Nature, 460(7256):748–52, Aug
2009.
92
[36] Jianxin Shi, Douglas F Levinson, Jubao Duan, Alan R Sanders, Yonglan Zheng, Itsik
Pe’er, Frank Dudbridge, Peter A Holmans, Alice S Whittemore, Bryan J Mowry, Ann
Olincy, Farooq Amin, C Robert Cloninger, Jeremy M Silverman, Nancy G Buccola,
William F Byerley, Donald W Black, Raymond R Crowe, Jorge R Oksenberg, Daniel B
Mirel, Kenneth S Kendler, Robert Freedman, and Pablo V Gejman. Common variants
on chromosome 6p22.1 are associated with schizophrenia. Nature, 460(7256):753–7,
Aug 2009.
[37] Hreinn Stefansson, Roel A Ophoff, Stacy Steinberg, Ole A Andreassen, Sven Cichon,
Dan Rujescu, Thomas Werge, Olli P H Pietiläinen, Ole Mors, Preben B Mortensen, En-
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István Bitter, János M Réthelyi, Brynja B Magnusdottir, Thordur Sigmundsson, Pall
Olason, Gisli Masson, Jeffrey R Gulcher, Magnus Haraldsson, Ragnheidur Fossdal,
Thorgeir E Thorgeirsson, Unnur Thorsteinsdottir, Mirella Ruggeri, Sarah Tosato, Bar-
bara Franke, Eric Strengman, Lambertus A Kiemeney, Ingrid Melle, Srdjan Djurovic,
Lilia Abramova, Vasily Kaleda, Julio Sanjuan, Rosa de Frutos, Elvira Bramon, Evan-
gelos Vassos, Gillian Fraser, Ulrich Ettinger, Marco Picchioni, Nicholas Walker, Timi
Toulopoulou, Anna C Need, Dongliang Ge, Joeng Lim Yoon, Kevin V Shianna, Nel-
son B Freimer, Rita M Cantor, Robin Murray, Augustine Kong, Vera Golimbet, Angel
Carracedo, Celso Arango, Javier Costas, Erik G Jönsson, Lars Terenius, Ingrid Agartz,
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APPENDIX A
POST-MORTEM DLPFC MIR-137 CASE-CONTROL STUDY
Postmortem expression analysis by Guella et al.(2013) shows a significant decrease in
miR-137 expression for rs1625579 minor allele carriers in the control group (Figure A.1).
However, this genotype dependent decrease is not seen in patients, supporting a potential
gain-of-function pattern in patients.
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MiR-137 Expression in Post-mortem Dorsolateral Prefrontal Cortex
Figure A.1: Results from Guella et al. found rs1625579 genotype association with post-
mortem expression levels of miR-137 in the DLPFC. miR-137 expression was significantly
associated with genotype in controls. Control individuals who were carriers of the rs1625579
“G” allele had significantly increased miR-137 expression. However this pattern is not ob-
served in patients indicating potential upregulation for the minor allele patient group.80
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APPENDIX B
EFFECTS OF DEMETHYLATION ON TRANSCRIPT EXPRESSION IN
VITRO
B.1 Introduction
Increased DNA methylation of the MIR137HG locus is associated with decreased miR-
137 expression. DNA methylation is also known to both up- and down-regulate alternative
splicing through several different mechanisms. Increased DNA methylation up-regulates
alternative splicing by preventing the binding of factors such as CTCF. Down-regulation of
alternative splicing via DNA methylation has been shown to occur when MECP2 binds to
methylated alternative exons and enhances their inclusion. This is thought to occur through
altered Pol II kinetics. We predicted that differential DNA methylation of the region due to
VNTR length may contribute to the association with alternative splicing.
To test these hypotheses in vitro we cultured human neuroblastoma cells treated them
with a demethylating agent and evaluated transcript expression and DNA methylation using
custom del-miR-137 qPCR and pyrosequencing primers respectively.
B.2 Methods
B.2.1 Cell Culture and AZA treatment
SH-SY5Y cells were cultured in media for four days. After cells were plated they were
allowed to grow for 24 hours before demethylation treatment. Before harvesting, cell viability
was evaluated using Trypan Blue Solution. Cells were treated in either 5µM DMSO only or
5µM 5′-AZA-2′ dissolved in DMSO for four days. Media was changed on days 1, 2 and 4.
B.2.2 DNA and RNA Processing
DNA was extracted using standard protocols for the QIAGEN DNeasy kit (cat. #65904).
RNA was extracted using standard protocols for the QIAGEN RNeasy kit (cat #74104).
Bisulfite conversion of extracted DNA was carried out using standard protocols for the
QIAGEN EpiTect Fast DNA Bisulfite kit (cat. #59824)
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B.2.3 Pyrosequencing
Pyrosequencing was conducted on a PyroMark Q96 MD instrument. Eight CpG sites
were evaluated using two custom primer pairs (Forward: GGGAGAGGTGAAGGGGATG,
Reverse: CCCAAACTACTCAAAACCT; Forward: AAGGGGTGGAGAAATAGGA, Re-
verse: ACTACCTACCCCAACCTCT) and one previously described primer pair (For-
ward: GAAGTAGTAGAGTATAGTTTTGGATTTTTT, Reverse: ACCCCCCCCTACC-
TAAAAATAAACTAA).124 Pyrosequencing was carried out in replicates of four for all three
primer pairs.
B.2.4 qPCR
Potential impacts of global DNA demethylation on alternative splicing was evaluated
through cDNA synthesis and qPCR using custom primers for del-miR-137 and pri-miR-
137 transcripts. The forward primer used to evaluate del-miR-137 expression overlaps the
primary splice site to exon 5 junction with the reverse in E5. The forward primer used to
evaluate pri-miR-137 transcripts is located in the end of exon 3 which is spliced out in the
del-miR-137 transcripts, and the same E5 reverse. Relative expression was evaluated using
the ∆∆ Ct method for fold change between treated and untreated groups with the GAPDH
housekeeping gene.
B.3 Results
B.3.1 Cell Culture Morphology
Cells cultured in AZA were slower growing and the majority of cells were in suspension.
In contrast, the DMSO control cultures contained cells were both adherent and suspended
cells. This differential morphology indicates that AZA treatment is impacting cell adhesion
in a manner consistent with previous methylation studies of SH-SY5Y cells using AZA. This
is an indicator that treatment protocol was successful. We additionally attempted to verify
this result through pyrosequencing analysis of the MIR137HG region.
B.3.2 Pyrosequencing
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Results of the pyrosequencing at four of the analyzed CpG sites showed no methylation
relative to control samples in either control or treated culture groups, marginal demethylation
of the treated cells at two CpG sites, and a marginal increase in methylation of the treatment
group at the last CpG. This result likely indicates that DNA extraction protocol may have
ablated methylation, as we failed to replicate a previously validated mCpG site within the
MIR137HG .124 However, marginal demethylation in the AZA treated cells may indicate that
there was a slight effect of treatment. Ultimately, these results are inconclusive and do not
allow verification of the AZA treatment protocol.
B.3.3 qPCR
QPCR results can be found in Table B.1. For both primer sets transcript expression was
increased in the demethylated treatment group with a 2.92 expression fold change for the
del-miR-137 transcripts and a 1.75 expression fold change for the pri-miR-137 transcripts.
B.4 Discussion
Our previous results demonstrated an association between VNTR length and pri-miR-
137 transcript splicing. DNA methylation is associated with alternative splicing and is also
associated with SZ. The high GC content of the VNTR lead us to hypothesize that DNA
methylation may contribute to the association between the VNTR and alternative splicing.
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GAPDH 20.99 20.94 20.98 20.96 19.87 19.93 19.99 19.96 20.97 19.94
E3 End 26.42 26.61 26.56 26.43 26.17 26.30 26.33 26.33 26.51 26.28 5.54 6.35 -0.81 1.75
SS’ + E5 28.71 29.29 29.83 29.65 29.75 29.78 30.27 29.73 29.37 29.88 8.40 9.95 -1.55 2.92
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Although inconclusive, results of pyrosequencing may indicate that there is minimal
DNA methylation within the VNTR region. In vitro demethylation treatment effects on
pri-miR-137 and del-miR-137 transcript expression showed increased fold changes for both
transcript variants indicating an overall increase in transcript expression after demethyla-
tion treatment. The increased fold change in the del-miR-137 transcripts indicates that
decreases in global methylation may up-regulate alternative splicing. Pyrosequencing ex-
periments will need to be replicated to determine effects of proximal DNA methylation on
alternative splicing. Although the fold change for del-miR-137 transcripts was higher than
the pri-miR-137, increased pri-miR-137 expression would result in increased mature miR-
137 expression. These findings are consistent with hypomethylation associations found in
patients as hypomethylation would contribute to gain-of-function miR-137 risk. These re-
sults demonstrate changes in mature miR-137 expression due to altered DNA methylation
independent of alternative splicing.
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